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Abstract 
Cancer is a worldwide issue affecting millions and the need for understanding 
specific mechanisms linked to its progression has never been higher. One of the 
biggest challenges in cancer research is the complexity of the tumour 
microenvironment (TME) which not only consists of cancerous cells, but auxiliary 
lymphocytes, macrophages, blood vessels and the extracellular matrix (ECM). 
There is therefore a need to unravel the impact of these specific components on 
cancer cells by deconstructing their environment. In this study, we aim to understand 
fundamental cell-ECM interactions by breaking down the complex TME to its 
building blocks: the cancer cell and the ECM.  
We use poly(alkyl acrylates) material surfaces which have been shown to direct the 
organisation of fibronectin (FN), a key ECM protein, upon adsorption to study cell 
behaviour such as adhesion, growth, migration and drug resistance. Here we show 
that poly(methyl acrylate) (PMA) and poly(ethyl acrylate) (PEA) are able to organise 
FN into globular and fibrillar conformations respectively upon adsorption, thus 
exposing or concealing specific integrin binding domains such as the RGD cell 
binding domain and the PHSRN synergy sequence.  
With these conditions, we assess: cell adhesion through studying attachment, focal 
adhesion formation and single cell traction on the surface of the polymers; cell 
migration by looking at the speed of gap closure in wound healing assays; drug 
resistance by studying cytotoxicity of a well-established anticancer drug in docetaxel 
as well as PND-1186 (VS-4718) which is a novel drug currently in phase 1 clinical 
trials; and intracellular signalling by quantifying protein expressions of focal 
adhesion kinase (FAK). Furthermore, we conduct a preliminary study of cancer cells 
in a highly tuneable poly ethylene glycol (PEG)-based 3D system functionalised with 
the RGD cell binding domain. We analyse hydrogel stability, cell viability and cell 
invasion.  
We demonstrate that upon adsorption to the polymers the fibrillar and globular forms 
of FN lead to the PHSRN synergy sequence being more exposed on PEA compared 
to PMA respectively. This is shown to have significant impact on cell anchorage, 
mediated primarily by the RGD domain of FN via integrin αvβ3, and cell motility which 
is mediated by both the RGD and PHSRN sequences via integrin α5β1.  
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We also demonstrate that although this 2D model provides essential information for 
cell-ECM interactions, it does not take into account the 3D environment. We show 
that cells are able to interact with the proposed PEG-based hydrogel and that it can 
be fine-tuned by altering gel stiffness and functional components independently.  
Overall, the methods and systems used in this study have allowed for a better 
understanding of the material-protein and the cell-protein interfaces and how they 
affect cell behaviour in regard to adhesion, migration and invasion. 
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1 Introduction 
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1.1 An overview of biomedical engineering 
1.1.1 Introduction and brief history 
The field of biomedical engineering (BME) is a rapidly growing area of research that 
has evolved over the past few decades. The term describes an interdisciplinary 
science in which mechanical, chemical and electrical engineering principles are 
used for a vast array of medical and biological applications such as bioinformatics, 
biomedical optics, medical devices, biomechanics and tissue engineering, among 
others1, 2.  
On a cellular level, the evolution of the area of BME has allowed the development 
of cellular and molecular biomechanics, which studies the conversion of mechanical 
stimuli to biological responses, as well as synthetic biology which is the design and 
construction of biological models such as modified amino acids and nucleotides, 
and custom-designed proteins and enzymes among others3, 4. Both interdisciplinary 
fields have been used to gain further understanding in cellular behaviour with 
research, diagnostic, therapeutic and preventative applications. The development 
of biosensors in the medical field has allowed more precise ways of diagnosing 
infectious diseases, identifying patients prone to heart failure, and are proving to be 
a powerful tool in cancer diagnosis through the detection of cancer-related 
biomarkers. Recent studies have shown that the use of engineered surfaces can 
affect cell adhesion, migration and proliferation, highlighting the importance of cell-
material and cell-protein interactions and the dependence of the extracellular 
matrix5. 
 
1.1.2 Biological functions 
These studies demonstrate how biomedical engineering is useful in understanding 
biological functions due to their naturally complex nature. Standard studies of cells 
are carried out in vitro with the use of tissue culture plastic (TCP), with the focus 
being on one cell line and understanding the physiological response as a response 
to different external stimuli i.e. drugs, enzymes, etc. This simplified model has 
shown its limitations with the fact that cells in vivo have very different configurations 
and external stimuli compared to cells on TCP. In natural conditions for a vast 
majority of tissue cells are in a 3-dimensional setting surrounded by other cells of 
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the same line, different cell types and the ECM providing them with much different 
biological and mechanical stimuli6, 7. 
Many 2D models of tissue culture take into account proteins of the ECM such as 
fibronectin, collagen, vitronectin, laminin, etc. with the addition of foetal bovine 
serum to allow cell adhesion and spreading8-10. However, these models ignore the 
influence of paracrine and endocrine signalling of other cell types which secrete 
essential proteins such as growth factors necessary for cell development. BME 
seeks to improve these models with the use of polymers and hydrogels that can be 
used to mimic in vivo conditions (Figure 1).  
 
Figure 1: Applications of cell culture from 2D to 3D. Traditional cell culture is 
carried out on standard TCP or glass that are treated with ECM proteins 
allowing cell adhesion and studying specific cell-protein interactions. Cells 
cultured on top of hydrogels allow for the study of cell traction, looking at the 
mechanotransduction of forces between the cell and its close environment. 
Sandwich cultures are used to study the effects of apical and basal stimuli of 
cells. Cells cultured inside of hydrogels are used to study cells in a fully 3D 
setting.  
 
Polymers are used and fine-tuned to replicate the stiffness of the natural cellular 
environment and study the influence of stiffness on cell behaviour. Many biomaterial 
surfaces are used in cell culture depending on the aim of the study. 2D hydrogels 
are used to provide a substrate that is not super physiologically stiff such as plastic 
or glass11, 12. This allows cells to have a less aberrant phenotypes such as flat cells 
with a large amount of stress fibres. It is well documented that substrate stiffness 
has a significant impact on cell behaviour such as differentiation and proliferation12 
so biomaterials such as polyacrylamide (PAA), collagen, alginate, polyethylene 
glycol (PEG), and hyaluronic acid (HA) are useful to study cells in an environment 
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with more controlled, physiologically relevant stiffness’13, 14. Furthermore, it is 
possible to control the proteins cells are exposed to using these biomaterials. 
Adhesive ligands such as RGD can be cross-linked to the majority of these 
substrates if they do not present any natural binding sequences11 as well as other 
protein sequences of interest. This allows a more in depth understanding of specific 
cell-protein interactions.  
Co-culture systems grow two distinct cell types, often separated by a physical 
boundary while allowing the transfer of proteins and molecules, to understand their 
interaction and the influence of one cell line on the other. Sandwich cultures are 
developed to provide both basal and apical stimuli to cells. Hydrogels are used with 
ECM protein components in order to grow cells in a 3D environment11, 15-18. 
These methods all present their respective advantages and inconveniences with a 
study of several of them being useful to gain a more complete understanding of 
biological functions. 
 
1.1.3 Applications in cancer research 
The study of cancer is a representative example in understanding the limitations of 
simple 2D systems on TCP and the need for more innovative methods. Tumours 
are complex organs within the body composed of not only the cancer cells 
themselves, but of various auxiliary cell types such as neoplastic cells, fibroblasts, 
immune cells and endothelial cells19 (Figure 2). These are all maintained by blood 
vessels that irrigate them and held together by the ECM. This protective and 
nurturing environment provides cancer cells with the opportunity to proliferate, 
spread, and develop resistance to several drugs. A large number of studies now 
show the link between cancer treatment resistance and components of the tumour 
microenvironment (TME). For example, breast cancer cells develop resistance to 
tamoxifen, a selective oestrogen receptor modulator, via fibronectin and the β1 
integrin20, 21. Moreover, the use of tamoxifen has been shown to increase the 
expression of an ECM gene cluster. This example is among many that show that 
the tumour’s response to therapy is modulated by the TME.     
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Figure 2: Schematic illustration of a typical TME. Tumour cells are 
surrounded and protected by diverse auxiliary cell types (such as endothelial 
and epithelial cells, fibroblasts, macrophages, and lymphocytes) and ECM 
proteins (such as collagen, fibronectin, laminin...etc.). Image from Xian Xu 
201419 (© 2014, Elsevier). 
 
Until recently, the in vitro study of cancer cells has failed to realise the importance 
of the TME and take into account the complex factors needed to fully understand 
cancer. Cells are grown on tissue culture treated polystyrene but this simplified 
model does not consider key factors of the cells environment such as accessory 
cells and ECM proteins. More and more studies are being carried out using 
biomimetic models of components of the TME and the ECM. Electrospun fibres are 
used due to their structural and topological similarities with the ECM and are a 
promising tool in understanding cancer cell migration but also for bone and neural 
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regenerative applications22-24. More in vivo like approaches are also being used with 
3D culture models that take into consideration structural and mechanical properties 
not replicable in a 2D system. These systems are however not yet perfected as 
there is still limited special organisation and interaction between cells which does 
not allow a better understanding of mechanisms involving cell-cell and cell-ECM 
interactions. The 3D system is preferably used to better understand cell migration 
and not simplified interactions.  
Many in vitro tumour models are currently being looked at to understand the 
mechanisms involved in cancer progression such as growth, migration, metastasis 
and drug resistance in order to develop novel therapies and screen potential drug 
candidates. There are 4 main models which are used to screen drug candidates and 
understand metastasis: transwell-based models, spheroids, hybrid models, and, 
tumour-microvessel models25.  
Transwell-based models are widely used for invasion and migration assays26, 27 
which consist of analysing the movement of the cells from one area to another either 
spontaneously or with the help of an external stimuli such as gradients in media, 
substrate stiffness or electrical fields. Migration deals with cell movement on the 
surface of a substrate (in the 2D context) or within a substrate (in the 3D context), 
whereas invasion consists of the ability of cells to penetrate a 3D ECM substrate. 
Transwell-based assays exist for both types of behaviours and are able to assess 
and compare the metastatic potential of different cell types with combinations of 
various ECM proteins, drugs and treatments, as well as gene modification. This 
method has the advantage of being relatively low-cost and high throughput but due 
to the fact that only single-cell motility is taken into account, it has little physiological 
relevance. 
Spheroids are grown in suspension or in 3D ECM. They are multicellular aggregates 
that represent avascular tumour nodules or micro-metastases25, 28. They are used 
primarily for drug testing, proliferation, angiogenesis, as well as the effects of 
hypoxia on metastasis and tumour progression. This model helps understand cell-
cell and cell-matrix interactions in a 3D setting as well as the tumour’s interaction 
with its environment. Although being more expensive and needing more preparation 
time than 2D models, a clear advantage of spheroids is the ability to mimic in vivo 
tumours with nutrient and proliferation gradients with the development of necrotic 
cores28, 29.   
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Hybrid models are a compromise between the elaborate TME and a straightforward 
in vitro model, consisting of properties observed in transwell and spheroid systems. 
For example, ex vivo tumour sections can be collected from patients by biopsy and 
embedded into an ECM substrate to determine an adequate chemotherapy 
treatment or even to study proliferation (Brown 2004, Xu 2013). 3D invasion models 
are studied by seeding cancerous cells on the surface of an ECM substrate and 
tracking individual movements and trajectories of cells through the hydrogel which 
gives insight into the effects of matrix stiffness and composition on cell adhesion 
and invasion30, 31. These techniques are useful for fine-tuning the TME and using 
patient-specific cells which can lead to patient specific treatment approaches but do 
not mimic the in vivo effect of angiogenesis and vasculature formation.  
Tumour microvessel models take into account a commonly overlooked but rapidly 
growing area of interest in cancer studies32, the supplementation of oxygen and 
nutrients to the tumour allowing proliferation and eventually metastasis through the 
formation and development of blood vessels. According to Butler et al. the 
endothelial cells that line blood vessels secrete factors that promote and repress 
tumour growth33 highlighting their importance in cancer proliferation. This model is 
used to study the interaction between cancer cells and the microvessel, more 
specifically metastatic components such as intravasation into the vessel and 
extravasation out of the vessel.    
Although many of these models are able to mimic some physiological factors such 
as vascularisation, invasion, degrees of hypoxia and their role in tumour 
progression, the study of fundamental cell-cell and cell-protein interactions proves 
to be difficult from a quantitative point of view. These basic interactions are important 
in understanding how cancer cells survive, divide and recruit other cells using ECM 
proteins.  
 
 
 
 
 
1.2 The ECM 
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The extracellular matrix (ECM) is a complex structure of proteoglycans which form 
a hydrated gel filling up most of the intercellular space and various fibrous proteins 
such as collagen, fibronectin and laminin among others34. These components, 
produced mainly by fibroblast and other connective tissue cells are essential for 
holding together the cells of multicellular organisms in tissues and organs 34. The 
ECM bridges between cells, provides mechanical support to tissues and is a source 
of signalling cues that are important for cell survival, proliferation, differentiation and 
migration35, 36. It is a highly dynamic network that communicates with cells through 
bi-directional integrin signalling, in conjunction with growth factors, that is inside-out 
(cells being able to rearrange the external ECM environment) and outside-in (ECM 
proteins being able to direct cell behaviour). Moreover, the ECM provides 
mechanical signalling with the cells being able to sense differences in ECM stiffness 
and respond accordingly37. 
According to J. Engel and M. Chiquet, the ECM is made up of multidomain proteins 
that sometimes act in a concerted fashion forming lateral interactions that allow the 
formation of fibres and a network38. Of the many domains in ECM proteins, cadherin, 
epidermal growth factors, TGF-β (transforming growth factor) and RGD binding 
domains are among the most notable. These proteins are highly involved in the 
signalling processes of many growth factors such as TGF-β, VEGF (vascular 
endothelial growth factor), and, EGF (epidermal growth factor)39. Collagen is 
secreted primarily by connective tissue cells and is the major protein of the ECM, 
making up to 25% of total protein mass in mammals40. Well documented disorders 
such as Marfan syndrome are linked to mutations and alterations to this structural 
ECM protein41. Fibronectin (FN), a specialized ECM protein, is one of the most 
studied due to its known implication in cell binding via the RGD domain and is thus 
essential in understanding cell-protein interaction.  
 
1.2.1 Fibronectin 
Fibronectin is synthesised in many cell types although it is primarily produced by 
fibroblasts and mesenchymal cells. Besides the ECM, FN can also be found in the 
plasma (necessary for wound healing)42, synthesised by hepatocytes. It is a dimeric 
glycoprotein consisting of two subunits of 220-270 kDa and one of the main 
components of the ECM contributing in cell interactions and regulating cell growth 
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and migration43-45. This protein consists of a multimodular structure made up 
principally of three types of amino acid repeat domains termed FN-I, FN-II and FN-
III (Figure 3). FN monomers consist of 12 FN-I, 2 FN-II and 15-17 FN-III repeats 
responsible for binding with other ECM proteins such as collagen and fibrin, other 
FN molecules to form networks, integrins presented at the cell surface, and growth 
factors43. 
 
Figure 3: Structure of a fibronectin dimer with different repeat domain types 
and binding sites. Fibronectin is formed of repeat types I, II and III as well as 
a variable region. These repeats serve as binding sites for other ECM 
proteins such as fibrin and collagen. A cell binding site is located on the 9th 
and 10th type III repeat (FN-III9-10) via PHSRN and RGD sequences 
respectively. Image adapted from Hynes, R.O. et al.46 
 
Among the domains on FN, the Arg-Gly-Asp (RGD) cell binding domain is one of 
the most important as it binds cells via the α5β1 and αvβ3 integrins47. Another 
important domain in cell binding is the PHSRN synergy sequence that increases cell 
binding via the α5β1 integrin48-50. These domains are very close, at about 30 Å in 
distance from each other51, 52 and are responsible for integrin binding and the 
formation of focal adhesions (FAs), anchor points of the cell in the ECM (Figure 4). 
Although it is largely believed that the RGD domain is essential for cell binding, 
some studies have shown that cells attach to FN when the RGD domain is 
deactivated but attachment decreases when the PHSRN domain is deactivated 47-
49, 52. Furthermore, studies have shown that cells also bind to FN using the 
selectively expressed αvβ6 integrin53 and that the inhibition of αvβ3 expression led to 
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the inhibition of cell migration and invasion and an increase in apoptosis54. This 
suggests that there is a more complex interaction involved in cell binding possibly 
via other ECM proteins and integrins. 
 
 
Figure 4: FN-III7-10 model showing RGD and PHSRN binding sites and 
epitopes for antibodies blocking them. HFN7.1, and mAb1937 are used in 
this thesis to block the RGD and synergy sequences respectively. Image from 
Michael, K. E. et al.55 (© 2003, American Chemical Society). 
 
1.2.2 FN-integrin signalling 
Integrins are transmembrane protein receptors responsible for the adhesion and 
communication of cells with the surrounding extracellular matrix. They form a link 
between ECM proteins and the actin cytoskeleton and once bound, intracellular 
signalling pathways are activated leading to response in cell binding, FA formation, 
spreading, growth and proliferation (Figure 5).  
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Figure 5: Integrin and ECM interaction. (A) Schematic of integrin with ECM 
and intracellular proteins from Kinbara, K. et al.56 (© 2003, Springer Nature). 
The activation of integrins depend on their interaction with the ECM and 
intracellular components such as FAs and the cytoskeleton. (B) Different 
combinations of α and β integrin subunits and their ECM ligand. 
 
They are found in a large number of animal species and are non-covalent 
heterodimers composed of two main sub-units, α and β with large extracellular 
domains that bind to the ECM and short cytoplasmic domains that link to the 
cytoskeleton. There are 18 and 8 different types of α and β sub-units, respectively 
which combine to form at least 24 distinct integrin heterodimers57. The most notable 
heterodimers in regard to FN signalling being α5β1, α8β1, αIIbβ3, αvβ3 which are major 
factors in cell binding with the RGD domain and PHSRN synergy sequence on the 
FN-III7-10 repeats.  
The binding of FN to integrin induces the formation of adhesion complexes that are 
initially small in length and area with FA proteins such as talin, tensin and vinculin 
linked to the actin cytoskeleton, known as focal complexes. Integrins then form 
clusters, recruiting more FA proteins such as paxillin, α-actinin and focal adhesion 
kinase (FAK) forming larger FA complexes leading to the formation of actin stress 
fibres (Figure 6)58-60. 
 
Figure 6: Schematic representation of FA components58. (A) Adhesion 
complexes are formed initially when integrins bound to the ECM recruit 
primary FA proteins such as talin, tensin, and vinculin. (B) Mature FAs form 
after time when more FA proteins are recruited such as FAK and paxillin, 
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binding to other integrins and making the FA stronger. Images from the 
University of Reading – Cell adhesion (2017)58. 
 
These focal adhesions are very dynamic, disassembling and reassembling within 
active and highly mobile cells allowing migration using the ECM as a scaffold61-63. 
Moreover, there is a distinct relationship between forces on the ECM and FA 
formation with stiffer surfaces leading to an increase in FA size64-66.  
 
1.2.3 Fibrillogenesis: cell-mediated and material-driven 
Not only does FN interact with cells, it also interacts with other FN proteins, 
assembling into a network. FN is secreted as a soluble dimer, but then undergoes 
conformational changes that expose hidden sites that promote its polymerization 
into insoluble fibrils67-69. Although it is known that fibrillogenesis is mainly a cell-
mediated process, the controlling factors are not fully understood. In this process, 
soluble FN binds to integrins. This causes FN to be coupled with the actin 
cytoskeleton that can exert forces on the bound proteins causing them to unfold. 
The unfolded FN molecules interact with each other and associate resulting in the 
formation of a matrix70.  
Studies suggest that fibrillogenesis is also possible in the absence of cells by 
applying force, shear, using denaturants as well as when FN is adsorbed on different 
substrates that promote the unfolding of FN68. Furthermore, cells can interact with 
these biomaterials via the FN on its surface by recognising and attaching to the 
adsorbed FN and in turn remodel the two-dimensional FN network. Material-driven 
fibrillogenesis is possible on some poly acrylates such as poly (ethyl acrylate) (PEA), 
whereas this is not observed on poly (methyl acrylate) (PMA), even if the two 
polymers are very similar chemically71. 
PEA and PMA are both hydrophobic rubber-like polymers that are very similar in 
structure and physico-chemical properties. The following (Table 1) depicts physico-
chemical properties comparing both polymers. 
 
Table 1: Properties of PEA and PMA 
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Polymer PEA PMA 
Structure 
  
Molecular formula C5H8O2 C4H6O2 
Glass transition temperature -21°C 9°C 
Density (25°C) 1.12 g/cm3 1.22 g/cm3 
MW of repeat unit 100.12 g/mol 86.09 g/mol 
 
 
These two acrylates have very similar properties, the only structural difference being 
a slightly longer side chain for PEA. That leads to a noticeable difference in the glass 
transition temperature. Further surface chemistry studies carried out on these 
polymers show similar wettability and total amount of FN adsorbed68. However, the 
conformation of the adsorbed FN is drastically different. On PEA, FN is organised 
as an interconnected network whereas on PMA FN is dispersed in a globular form68, 
72. This has a direct effect on cell function and more particularly on cell differentiation 
and formation of FAs. These differences are possibly due to conformation of FN on 
these surfaces. When FN is unfolded when adsorbed to PEA, more domains such 
as the cell binding sequence are available as opposed to folded FN on PMA67, 73, 74. 
Although the cell binding domain appears to be more available on PEA, the effects 
of cell binding and attachment have yet to be studied. 
PEA is able to induce material-driven fibrillogenesis and serves as a biomimetic of 
cell-mediated fibrillogenesis as opposed to PMA. This can be used as a model to 
better understand fibrillogenesis in general and how cells interact with FN depending 
on its conformation. This is important in order to study and characterise cell function 
where the ECM and more particularly FN plays an important role such as in 
differentiation and proliferation. One potential application is understanding the role 
that FN has in cancer cell proliferation and metastasis. 
 
1.3 Fibronectin and cancer 
1.3.1 Cancer 
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Cancer is an abnormal growth of cells forming tumours, caused by several factors 
such as changes in gene expression that lead to dysregulation of cell proliferation 
and death. Although it is difficult to estimate the total number of people with cancer 
worldwide there were over 14 million new cases in 2012 alone with a projected 
increase to 24 million new cases of cancer per year by 203575. The most common 
forms being of the lung, breast, colorectal and prostate cancer, resulting in over 8 
million deaths worldwide in 2012, it has become the leading cause of mortality in the 
UK surpassing heart disease76. The need to understand the genetic and 
environmental causes as well as the cellular and molecular mechanisms involved 
have never been more relevant for the development of treatments.  
Over the past few years, many advances have been made in understanding the 
biology and genetic mechanisms at play in cancer progression77-79. The main 
categories of cancers include carcinomas (epithelial cells), sarcomas (bone, 
cartilage), leukaemia (blood, bone marrow), lymphoma and myeloma (immune 
cells) and nervous system cancers (brain, spinal cord). Carcinomas are the most 
common type of cancer (85% of cases in the UK) and develop within cells that 
comprise epithelial tissue which line and cover the outer body (skin) as well as the 
organs and body cavities75.  
The process through which cancerous cells develop, mutate, form tumours, recruit 
other cells and blood vessels is known as tumorigenesis. This begins with a series 
of mutations of several genes within a cell, known as oncogenes and tumour 
suppressor genes, which regulate cell growth, proliferation and death. An increase 
in oncogenes such as ras and myc which upregulate cell proliferation and a 
decrease in tumour suppressor genes such as p53 and PTEN which upregulate 
apoptosis leads to a rise in mutated cells. Once enough cancerous cells are present, 
the solid tumour outgrows blood supply and the centre of the mass is deprived of 
oxygen. This phenomenon is thought to be a leading factor in metastasis as hypoxia 
upregulates the expression of metalloproteinase (MMP) enzymes that degrade 
ECM proteins, including FN, allowing invasion into surrounding tissue80-82.  
 
1.3.2 Cancer treatments 
1.3.2.1 Brief history of treatments 
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A wide range of treatments have been and are currently being used to treat tumours, 
from invasive surgical procedures to cancer gene therapy. Ancient surgeons would 
generally perform exploratory surgeries to locate and remove tumours only to see 
them reform83. The understanding that cancer cells were able to spread from the 
primary tumour and invade other tissue along with the advent of ultrasound, 
computed thermography (CT), magnetic resonance imaging (MRI) and positron 
emission tomography (PET) scans in the early 1970s have drawn attention to the 
fact that invasive surgeries, although important in the removal of the main tumour, 
are limited in effectiveness.  
In the early to mid-20th century radiation and surgery were predominantly used to 
treat cancer. The term “chemotherapy” was first described by German chemist Paul 
Ehrlich in 1914 to describe the use of drugs to treat infectious diseases84. He was 
also responsible for the documentation of the use of animal models to screen 
several chemicals to test their effectiveness against diseases. The first chemical 
agents tested in the early 1900s were arsenicals (based on arsenic) but had little 
success. In the early 1940s, nitrogen mustard was shown to kill lymphoma cancer 
cells that proliferated rapidely83. The mid-1940s to the 1960s saw the development 
of compounds such as thiopurines, and antitumour antibiotics, with the first talks of 
actually curing the disease. The field of chemotherapy has since evolved at an 
exponential rate with over 100 different drugs used. This was made possible thanks 
to the development of combination treatment (the use of several drugs), drug 
screening methods, and targeted therapies. In parallel, less invasive surgical 
techniques have recently been developed such as cryosurgery, which consists of 
freezing the tumour by spraying it with liquid nitrogen, or the use of miniature video 
cameras and endoscopy to remove certain tumours in the gastrointestinal tract or 
bladder83. Furthermore, advances in cell biology and oncology have given further 
insight into understanding the cancer machinery in order to develop treatments 
affecting specific mechanisms involved. The following Figure 7 provides a history of 
anticancer treatments. 
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B.
  
Figure 7: Key advances in the history of cancer chemotherapy. (A) The first half of the 20th century (1900 – 1960). (B) Second half of 
the 20th century to early 21st century (1965 – 2015). Images from DeVita V.T. and Chu E., 200884 (© 2008, AACR). 
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1.3.2.2 Chemotherapeutic drugs 
The bulk of chemotherapy drugs are cytotoxic, which inhibit metabolic function and 
stop reproduction or kill cancer cells altogether. Other drugs affect specific parts of 
the cell cycle, most notable the S or M phases. The different categories of 
chemotherapy drugs along with their mechanism of action can be seen in the 
following table 2. 
 
Table 2: Categories of chemotherapeutic drugs with their mechanism of 
action85  
Chemotherapy 
drug category 
Mechanism of action Examples of drugs 
Alkylating Agents Damages DNA by attaching 
an alkyl group to guanine.  
- Streptozocin 
(Zanosar®) 
- Thiotepa (Thioplex®) 
Kinase Inhibitors 
(Small molecule 
inhibitors) 
Blocks tyrosine kinase. 
Regulates cell proliferation 
and cell cycle. 
- Imatinib (Gleevac®) 
- Toceranib (Palladia®) 
- PND-1186 (Phase I) 
Vinca Alkaloids Halt cell division by 
preventing the formation of 
tubulin. 
- Vinblastine  
- Vinorelbine 
- Vincristine 
Anthracyclines Multiple factors such as 
intercalation with DNA and 
DNA binding proteins, 
binding of p53 to DNA 
inducing apoptosis.  
- Daunorubicin 
- Doxorubicin 
- Epirubicin 
- Valrubicin 
Antimetabolites Folic acid, analogues of 
pyrimidine and purine. 
Induction of cell death at the 
S phase by disrupting normal 
nucleic acid production. 
- 5-flurouracil (5-FU) 
- Capecitabine 
- 6-Mercaptopurine (6-
MP) 
- Methotrexate 
Aromatase 
inhibitors 
Interference with aromatase 
enzyme which reduces 
oestrogen production. Slows 
growth of oestrogen 
dependent tumours. 
- Exemestane 
(Aromasin®) 
- Anastrozole 
(Arimidex®) 
- Tamoxifen 
Topoisomerase 
inhibitors 
Binds topoisomerase 
enzymes which inhibits the 
rebinding of DNA after being 
cut. 
- Camptothecin 
- Doxorubicin 
- Etoposides 
- Mitoxantrone 
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These compounds have been proven to be useful and effective in the treatment of 
many types of cancers, but they lack specificity to the cancerous cells and often 
affect healthy cells.  
The characteristic of most chemotherapy drugs is that they attack rapidly dividing 
cells. However, many proliferating normal cells are damaged causing the well-
documented side-effects association with chemotherapy86-88. These drugs can 
cause sever local tissue necrosis, cardiotoxicity and myelosuppression among other 
destructive responses leading to fatigue, hair loss, nausea and vomiting. Other 
major difficulties faced with these treatments are drug resistance, which has been 
well documented, and the recurrence of tumours after treatment. 
Cancer cells develop drug resistance through various mechanisms such as drug 
inactivation, cell death inhibition, drug efflux and epithelial-mesenchymal transition 
(EMT)89, 90. The development of resistance of a few cancer cells after adjuvant and 
combination treatments can lead to the regrowth of the tumour, also known as 
recurrence91. 
These hurdles in the treatment of tumours places emphasis on the development of 
drugs and methods that are able to counteract the issues encountered with standard 
therapies.  
 
1.3.2.3 Targeted therapies 
The advancement of targeted therapies such as the use of monoclonal antibodies 
has had a profound impact on cancer treatment in recent years92. The exploitation 
of the immune system as a weapon against tumours has been studied since the 
beginning of understanding basic immune pathways. It has since displayed 
exceptional effectiveness in patients with various types of cancers93-95. This is done 
by recruiting the host’s immune system to recognise specific tumour antigens, which 
has shown to be effective in vitro96, 97 but represents a much more difficult challenge 
in vivo due to the tumour microenvironment (TME)98, 99. In order for immunotherapy 
to be successful the tumour antigens must be recognised in order to activate the 
immune system. This process is hindered by the microenvironment of surrounding 
accessory cells preventing the priming of lymphocytes and supresses the infiltration 
of effector cells100. 
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1.3.2.4 FAK inhibitors - PND-1186  
FAK is a potential target for anti-cancer therapy. PND-1186, also known as VS-4718 
is a substituted pyridine reversible inhibitor of FAK101. This small molecule inhibitor 
is currently in phase 1 clinical trials and has shown to promote tumour cell apoptosis 
in 3D environments and decrease tumour growth and spontaneous breast cancer 
metastasis in mice101, 102. With a reported in vitro IC50 of 1.5 nM and an in vivo IC50 
of ~100 nM101-103 this drug show promise for treating metastasis and fighting tumour 
progression as it targets one of the key components of cell anchorage and motility 
in FAK and therefore FAs. Although 3D and in vivo models have been used to study 
the efficacy of this drug, its effects on cell migration and FA formation have yet to 
be elucidated.  
Moreover, despite the anti-tumorigenic properties of these drugs, there are still 
concerns as to their non-specificity and therefore potential toxicity104. 
 
1.3.2.5 Matrix metalloproteinase inhibitors 
Matrix metalloproteinases (MMPs) are a large contributing factor in ECM structure 
and remodelling105. These enzymes secreted by the cell degrade surrounding ECM 
proteins such as collagen, fibronectin and laminin. There is a total of 24 known 
MMPs that are generally secreted at low levels are deregulated in many cancers 
allowing for degradation of the ECM and beginning the process of epithelial-
mesenchymal transition (EMT)106. This has caused MMPs to be of great interest in 
cancer treatment by developing MMP inhibiting drugs since the 1990s. 
Unfortunately, many of the drugs developed such as Batimastat, Marimastat, and 
Prinomastat that were all cancelled in Phase 3 of clinical trials due to poor solubility 
or insignificant efficacy107, 108. More recently, interest in MMPs as a therapeutic 
target has significantly diminished due to unsuccessful clinical trials. 
 
 
1.3.3 The epithelial-mesenchymal transition 
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The ECM is a fundamental component of the TME which serves as a niche for 
cancer and auxiliary cells such as fibroblasts and lymphocytes. In healthy conditions 
it helps to maintain tissues in a state of homeostasis109, however, within tumours it 
plays a pivotal role in the epithelial-mesenchymal transition (EMT). 
EMT, which was first described by Elizabeth Hay, is the process through which an 
epithelial cell that would normally interact with the basement membrane sustains 
changes that cause it to take on a mesenchymal cell phenotype with those 
characteristics110 (Figure 8). The newly acquired characteristics include an increase 
in the cell’s ability to migrate and invade other tissues, an increase in the resistance 
to apoptosis and a rise in the secretion of ECM proteins110-113. The biochemical 
processes implicated in EMT are numerous, enabling the different steps. These 
include but are not limited to: the activation of transcription factors, the expression 
of cell-surface proteins, the restructuring of intracellular cytoskeletal proteins, an 
increase in the production of matrix metalloproteinases (MMPs) which are ECM-
degrading enzymes111. 
 
Figure 8: The Epithelial-Mesenchymal transition with epithelial and 
mesenchymal markers. Cells begin with an epithelial phenotype but 
progressively lose epithelial markers which are replaced by mesenchymal 
markers. Image from Kalluri et al., 2009111 (© 2009, American Society for 
Clinical Investigation). 
 
This natural phenomenon has long been thought to occur solely during 
embryogenesis with epithelial cells being relatively flexible, possessing the ability to 
switch back and forth between epithelial and mesenchymal states. This occurs 
naturally with the process of EMT as well as the reverse process of mesenchymal-
epithelial transition (MET)113. Once embryogenesis and development is complete, 
cells usually lose their ability to differentiate. This, however, has been put into 
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question in light of observations of EMT to take place not only during the 
developmental stage but also into adulthood as it also plays an important role in 
tissue repair114, 115. 
Although the signalling pathways are not well defined or differentiated, there are 3 
subtypes of EMT recognisable by functional differences111, 116 (Figure 9). The first 
type of EMT being the classic case observed during morphogenesis. These cells 
are able to undergo EMT transformations as well as the reverse MET117.  
 
Figure 9: Different types of EMT and when they occur. (A) Type 1 EMT during 
embryogenesis which plays an important role in development. (B) Type 2 
EMT associated with tissue regeneration, leading to tissue fibrosis and 
inflammation. (C) Type 3 EMT linked to cancer progression and metastasis. 
Image from Kalluri et al., 2009111 (© 2009, American Society for Clinical 
Investigation). 
 
The second type of EMT is associated with healing and tissue repair. Key 
characteristics of this type of EMT are the formation of fibrotic tissue and 
inflammation118.  
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The third form of EMT is associated with metastasis and cancer progression and 
has been the most studied form. A main trait of epithelial cancers is the fact that 
cells proliferate excessively and new blood vessels form within the tumour119. Cells 
that undergo type 3 metastatic EMT begin by losing polarity and thus detaching from 
and infiltrating the basal membrane which also undergoes changes in ECM 
composition and therefore present altered cell-ECM signalling pathways. The 
second step in the process is the intravasation of mutated cells into the bloodstream 
followed by extravasation in distant tissue120, 121. Finally, cells adhere to the tissue 
forming metastatic colonies by undergoing the reverse mesenchymal-epithelial 
transition in some instances. The areas most frequently prone to being affected by 
cancer metastasis are the lungs and the liver making metastasis responsible for the 
largest number of cancer related deaths122-124. 
The signalling pathways implicated in metastatic EMT are not entirely clear. It is 
believed that the genetic alterations sustained by cancer cells in the primary tumour 
causing the disruption of cell-cell adherence junctions and the cell-ECM adhesions 
via integrins facilitates the activation of EMT programs125-127. 
It is therefore crucial to understand the interaction between cancer cells and their 
surrounding ECM environment at the molecular level in order to determine the 
mechanisms that dictate the migration of cancerous cells from the main tumour to 
other tissues. 
 
1.3.4 The importance of fibronectin in cancer 
As previously stated, one of the key aspects of EMT is the acquired ability of the 
mutated cells to increase their production of extracellular matrix proteins such as 
FN. Furthermore, cancer cells interact differently with their surrounding ECM 
proteins compared to normal cells. Their ability to disrupt the cell-ECM bond due to 
an increased production of matrix metalloproteinase (MMP) facilitates the process 
of EMT and therefore metastasis. Fibronectin, which is a main ECM component, 
plays a key role in this process and is a reasonable protein candidate to study these 
interactions at a closer level. The ECM and FN more specifically is essential in 
cancer cell adhesion and migration by serving both as a scaffold that cells can 
migrate on within the tumour towards blood vessels and as an anchoring point for 
cells seeking to attach to a host tissue away from the main tumour128. FN is known 
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to play an important role at several stages of tumour development129, 130. It has been 
shown to have a protective role against tumour necrosis factor-α-induced apoptosis 
by activating the AKT/Survivin pathway via β1 integrins in PC3 and LNCaP-LN3 
prostate cancer cells131. In ovarian cancer fibronectin activates the secretion of 
MMP-9 using the MEK1-MAPK and PI3K-Akt pathways which contributes to 
metastasis132. A study by Pontiggia et al. showed that fibronectin promoted 
tamoxifen resistance in human and mouse breast tumour via β1 integrins and 
subsequent activation of survival pathways21.  
 
Figure 10: Fibronectin signalling in healthy and tumorigenic cells. Fibronectin 
is responsible for many processes in healthy cells such as cell growth, 
differentiation, migration and wound healing. In tumorigenic cells, there is an 
upregulation of signalling pathways leading to abnormal growth, drug 
resistance, epithelial-mesenchymal transition and ultimately metastasis. 
Image from Wang J.P. et al. 2017133. 
 
Given the vast array of fibronectin’s implication in tumour progression (e.g. 
increased expression, cell migration/metastasis, therapy resistance), it is a focal 
point of cancer research with the potential to serve as a potent tool in therapeutic 
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targeting, but also as a means to understand the elusive interactions between 
cancer cells and their microenvironment. PHSCN, a competitive inhibitor of the 
activity of the PHSRN synergy sequence, has been shown to have antitumorigenic 
and antimetastatic properties49. Moreover, KAI1/CD82 which is a metastatic 
suppressor was shown to inhibit cell adhesion to ECM by suppressing the 
expression of FN134. These examples highlight the promising avenues in the 
research of fibronectin in cancer. 
 
1.4 Overall Aims of the Thesis 
This thesis aims to answer key questions and shed light on the role of fibronectin in 
cancer using innovative platforms. In particular, we are interested in investigated the 
role of fibronectin conformation (fibrillar vs globular) in cancer cell behaviour. The 
key goals of this project are: 
 
 Understanding and characterising the material-protein and protein-cell 
interfaces using fibroblasts (Chapter 2) 
Fibroblasts are well-studied cell types with known interactions with FN via integrins 
of interest for this project (α5β1 and αvβ3) 
 
 Studying the effect of fibronectin conformation on FA formation and cell 
migration in cancer cells (Chapter 3) 
Once methods have been refined with fibroblasts, a relevant cancer cell line will be 
used to assess FA formation and motility. 
 
 Directing the attachment and adhesion of L929 mouse fibroblasts and DU145 
human prostate cells by using FN-coated poly(alkyl) acrylates (Chapters 2 
and 3) 
Cells will be seeded onto poly(ethyl) acrylate and poly(methyl) acrylate substrates 
coated with FN. Upon adsorption unto these polymers, FN undergoes 
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conformational changes which can have an impact on the cell-protein interaction 
and therefore cell behaviour. 
 
 Clarifying the underlying mechanisms involved in the cell’s interaction with its 
environment (Chapter 3) 
The cell-protein interaction is key in determining cell behaviour but also ECM protein 
reorganisation via bi-directional integrin signalling. Gaining deeper insight in the 
intracellular pathways implicated in these processes is key in understanding the role 
of FN in cancer.  
 
 Developing novel methods for analysis of cell traction on polymers (Chapter 
3) 
A major component of cell motility is analysing the cells ability to modify and exert 
forces on its surroundings in order to migrate. Cell traction force microscopy is a 
known method for this purpose which uses polyacrylamide hydrogels or nanopillars. 
In order to take into account the material properties (stiffness) as well as protein 
conformation (FN on PEA and PMA), a novel computational technique is used to 
assess traction forces. 
 
 Studying cell behaviour in a simplified 3D model (Chapter 4) 
Having a 3D model is essential for studying cancer. They offer the advantage of 
mimicking in vivo conditions more faithfully but are often more expensive and are 
made up of complex components. Here we use a simplified and tuneable 3D model 
that could help understanding specific cell-protein interactions with the benefit of 
having a more natural structure as opposed to cells on tissue culture plastic. 
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2 Modulation of fibronectin activity and focal 
adhesion assembly with L929 fibroblasts 
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2.1 Introduction 
2.1.1 The use of fibronectin as a tool to direct cell response 
The need for a reliable cellular microenvironment that can be easily fine-tuned is 
important for cancer research and general biological research. In vitro cells are 
known to adhere to synthetic surfaces via an intermediate layer of protein. However, 
there is little to no control of the protein layer in traditional cell culture systems on 
tissue culture plastic, whereas the cell-protein interaction directly determines cell 
fate135, 136. Traditionally soluble ECM proteins such as FN, vitronectin and fibrinogen 
found in biological fluids like foetal bovine serum are intentionally deposited and 
adsorbed onto the synthetic surface135-139. The initial interaction between cells and 
this layer of protein is adhesion via integrins, which then determines cell fate through 
spreading, growth, differentiation, and viability. Being able to direct cellular response 
through controlling the protein layer using a reliable material-based system is useful 
for many applications in biomedical research such as regenerative medicines, tissue 
engineering and cancer research.  
FN, a fundamental ECM glycoprotein of high molecular weight found in extracellular 
fluids and connective tissue in its soluble and insoluble forms respectively, is a 
feasible protein choice to modulate in order to direct cell fate via integrins 44, 140-142. 
Cell binding via FN leads to the formation of FAs and the initiation of adhesive and 
migratory processes, which are fundamental characteristics in cell behaviour.  
 
2.1.2 FN-material interactions 
A large number of studies have shown that the amount and conformation of 
adsorbed FN can be altered by surface chemistry143-146. García et al. determined 
with the use of differently terminated self-assembled monolayers (SAMs) that 
hydrophilic surfaces induced little conformational changes to FN whereas 
hydrophobic surfaces lead to more significant structural changes55, 147. This shows 
that surface chemistry has a direct effect on protein conformation upon adsorption 
and can therefore influence its activity. It has been previously shown that PEA 
surfaces induce the organisation of FN protein into a fibrillar (nano) network 
conformation, comparable to their physiological state, upon adsorption on the 
polymer. Interestingly the use of PMA, whose monomer has one less methyl group 
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in the side chain, has a completely different effect, with a globular conformation of 
FN upon adsorption71, 148.  
 
2.1.3 Hypothesis and experimental aims 
We hypothesise that the differences in conformation of FN upon adsorption to PEA 
and PMA leads to differences in cell behaviour which suggests that it is possible to 
use these materials to modulate cell response via FN. In this study, the state of FN 
upon adsorption on PEA and PMA was characterised using various protein 
concentrations. L929 mouse fibroblasts were seeded on FN-coated PEA and PMA 
to determine cellular response in relation to the conformation of FN presented on 
the polymeric surface. The overall goal being the development of a tissue culture 
system that is both simple and reliable with which it is possible to fine-tune and 
control cellular behaviour via the modulation of activity of adsorbed protein, thus 
controlling the microenvironment that cells are exposed to. 
 
2.2 Materials and methods 
2.2.1 PEA and PMA sample preparation and FN coating 
Bulk polymers of PEA and PMA were prepared and supplied by the Universidad 
Politècnica de València. There, polymers were synthesised by radical 
polymerisation of ethyl and methyl acrylate (Sigma, St Louis MO).  
PEA and PMA were then prepared respectively at 2.5% and 6% (w/v) in toluene. 
These concentrations were used to have similar solution viscosities between PEA 
an PMA, making the spin coating process more uniform between polymers. 
Next, polymer solutions were spin coated onto 12 mm cover glasses. The 
parameters of the spin coating process for each polymer are listed in Table 3 below: 
 
 
 
 
Table 3: Spin coating parameters 
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 Velocity Acceleration  Time 
PEA 2.5% 2000 rpm 3000 rpm/s 30 s 
PMA 6% 3000 rpm 3000 rpm/s 30 s 
 
After spin coating excess solvent is removed by placing samples in a desiccator 
under vacuum for 60 minutes at 60°C. Samples are then stored under vacuum in a 
desiccator with silica beads in order to minimize humidity until ready to use.  
 
Human plasma FN (Sigma) was used in order to carry out experiments. FN was 
diluted in Dulbecco’s phosphate buffered saline with magnesium and calcium 
(DPBS++) and 200µl of FN at different concentrations (2, 5, 10 and 20 µg/ml) were 
then placed on the samples for 10 minutes or 1 hour. The solution was then removed 
and samples were rinsed twice using DPBS++. A further rinse using milliQ water 
followed by drying with a nitrogen flow was performed for WCA and AFM 
measurements. 
 
2.2.2 Water contact angle 
Water contact angle analysis was carried out on PEA or PMA surfaces alone and 
on FN coated surfaces. For each condition the static (SCA), advancing (ACA) and 
receding (RCA) contact angles were determined (n=9). Contact angles are 
determined by measuring the angle between the baseline and the drop as is shown 
in the following Figure 11.  
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Figure 11: Schematic representation of static, advancing and receding water 
contact angle measurements. Static WCA assesses the angle formed when 
the drop of water is in contact with the surface. Advancing and receding WCA 
respectively assess the maximum and minimum angles of the water droplet 
right before it advances or recedes.  
 
SCA was determined by placing a drop of 3 µl of water on the surface using a needle 
and recording the images at 12 frames per second for 30 seconds while measuring 
the angle of the drop with the polymer surface.  
ACA was determined by placing the needle in the previously deposited drop and 
progressively adding water in order to observe an increase in the length of the 
baseline. The ACA is the angle at which the baseline increases. 
RCA was determined by progressively removing the water with the needle until the 
drop has been removed. The receding contact angle is the angle at which the 
baseline starts decreasing. 
Hysteresis is defined as the difference between advancing and receding contact 
angles and is an indicator of the roughness and wettability of the surface.  
Measurements were carried out using a Theta optical tensiometer (Biolin Scientific). 
 
2.2.3 FN immunostaining 
Immunostaining was done with polyclonal anti-FN (Sigma) primary antibody 
directed against FN. PEA and PMA samples were coated with FN at different 
concentrations for 1 hour and 10 minutes. 
Freshly prepared samples were fixed with formaldehyde 4% for 30 minutes at 4°C 
and then washed three times with DPBS. Samples were then incubated with anti-
FN (1:400 dilution in DPBS/BSA 1%) for 1 hour at room temperature and then 
washed twice with DPBS/Tween20 0.5%. Samples were then incubated with Cy3 
anti-mouse (1:200 in DPBS++/BSA 1%) for 1 hour at room temperature in the dark. 
Samples were washed twice and mounted with mounting medium (Vectashield – 
Vector Laboratories, Inc. Burlingame, CA) and observed using an inverted 
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epifluorescent microscope (Zeiss AXIO Observer Z1, Jena, Germany). Images were 
taken at 5, 10, 20, 40, and, 63x magnification. 
 
2.2.4 Atomic force microscopy (AFM) 
In order to observe the protein conformation upon adsorption, samples were coated 
with FN for 10 minutes or 1 hour and rinsed twice with DPBS before being gently 
dried using a nitrogen flow. Surface height, lock-in phase, and lock-in amplitude 
were scanned using the Nanowizard 3 AFM from JPK in tapping mode. The 
cantilever used had a force constant of 3 N/m, a resonance frequency of 75 kHz 
and a pyramidal tip (MPP-21220, Bruker, Billerica, MA) with a radius curvature 
inferior to 8 nm. Several areas of each surface were scanned at the following area 
sizes and line rates: 5x5µm (0.5Hz); 2x2µm (0.7Hz); 1x1µm (1Hz); 0.5µm (1Hz). 
 
2.2.5 Micro bicinchoninic acid (BCA) protein quantification assay 
BCA protein quantification is a method that utilizes bicinchoninic acid (BCA) as the 
detection reagent for Cu+, which is formed when Cu2+ is reduced by protein in an 
alkaline environment. A purple-coloured reaction product is formed by the chelation 
of two molecules of BCA with one cuprous ion (Cu+). This water-soluble complex 
exhibits a strong absorbance at 562 nm that is linear with increasing protein 
concentrations149.  
PEA, PMA and glass cover slips were coated with FN for one hour at different 
concentrations. The coating was carried out by placing 200 µl of the different FN 
solutions on the cover slips for one hour. This was done in triplicates. 
During this time an albumin stock solution provided with the Micro BCA Protein 
Assay Kit (Thermo Scientific, Lot# OH189757) was diluted by serial dilution at 40, 
20, 10, 5, 2.5, 1.25, 0.625 and 0 µg/ml in order to obtain a standard curve. A stock 
solution of FN was also diluted at 20, 10, 5 and 2 µg/ml in order to determine the 
exact concentration of the stock FN solution and to be able to determine the actual 
amount of FN deposited onto the cover slips. 
After coating for one hour the FN solution is collected (about 200 µl) and placed into 
Eppendorf® protein LoBIND tubes (Sigma). The cover slips are rinsed with 200 µl 
of DPBS and the resulting solution is placed in the same tubes. 
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The albumin and FN standards as well as FN solutions were transferred to a 96-
well plate (150 µl per well in triplicates for albumin and FN standards and duplicates 
for each cover slip). 150 µl of BCA working reagent (a mixture of 25 parts BCA 
reagent A, 24 parts BCA reagent B and 1 part BCA reagent C) was added to each 
well. The plate was then shaken for 30 seconds, covered and placed in an incubator 
for 2 hours at 37°C. The plate was left to cool and absorbance was read using a 
Tecan NanoQuant Infinite M200 Pro plate reader at 562 nm. 
To obtain graphs from absorbance values, the blank of the albumin standard is 
removed from each well and the blank of each surface (FN0 – no fibronectin coating 
on PEA, PMA or glass) is removed from the respective wells. The results are 
therefore normalized according to the surface. The amount of protein adsorbed on 
each surface is then calculated via depletion. Knowing the total amount of protein 
on the coverslips (200 µl of 20 or 1 µg/ml of FN) and the concentration of FN 
remaining in the solution after coating, the amount of FN left on the surface was 
determined using the following equation. 
 
Equation 1: 
𝑨𝒅𝒔𝒐𝒓𝒃𝒆𝒅 𝑭𝑵 =  𝑻𝒐𝒕𝒂𝒍 𝑭𝑵 –  𝑴𝒆𝒂𝒔𝒖𝒓𝒆𝒅 𝑭𝑵 
 
Total FN: the amount of FN used to coat coverslips (200 µl x 20 µg/ml = 4 µg FN or 
200 µl x 1 µg/ml = 0.2 µg FN)  
Measured FN: 200 µl x BCA measured results  
 
 
2.2.6 Enzyme-linked immunosorbent assay (ELISA) 
The availability of the cell binding domain and synergy sequence of FN was 
measured by ELISA using HFN7.1 (DSHB, Iowa City, IA) and mAb1937 (Millipore) 
primary antibodies respectively. A horseradish peroxidase (HRP) coupled 
secondary antibody was used for absorbance reading. HRP is an enzyme which 
oxidises a substrate using hydrogen peroxide, resulting in a change of colour 
detectable by spectrophotometry at 450 nm (with a background reading at 550 nm). 
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Tests were first carried out using different dilution combinations of primary and 
secondary antibodies in order to optimize results for the actual experiments. HFN7.1 
was diluted at 1:32 and 1:128 combined with HRP-Goat Anti-Mouse (Invitrogen) at 
1:5000 and 1:10,000. mAb1937 and HRP-Goat Anti-Mouse were both diluted at 
1:10,000 and 1:20,000. For the test experiments, FN was adsorbed at 20 µg/ml and 
2 µg/ml on glass as well as a control without protein for 1 hour. Samples were 
washed with DPBS, transferred to 24-well plates and then blocked with DPBS/BSA 
1% for 30 minutes at room temperature. Next, samples were incubated with the 
primary antibodies at different dilutions (1:32 and 1:128 for HFN7.1 and 1:10,000 
and 1:20,000 for mAb1937) for 1 hour at room temperature and then washed twice 
with DPBS/Tween20 0.5%. The secondary antibody (HRP-Goat Anti-Mouse) was 
then added at different dilutions (1:5000 and 1:10,000 for HFN7.1; 1:10,000 and 
1:20,000 for mAb1937) for 1 hour at room temperature in the dark and then washed 
with DPBS/Tween20 0.5%. The substrate (colour reagents A and B from R&D 
systems) cv solution (R&D Systems) and transferred to a 96-well plate in order to 
read the absorbance. Absorbance was read using a Tecan NanoQuant Infinite M200 
Pro plate reader at 450 nm and 550 nm. 
In the case of the actual experiments, FN was adsorbed at 0, 2, 5 10 and 20 µg/ml 
on PEA and PMA. The same procedure was carried out for the actual experiments 
using HFN7.1, mAb1937 and HRP-Goat anti-mouse antibodies at 1:128, 1:20000 
and 1:10000 dilutions respectively which were the optimal combinations for the best 
results. 
 
2.2.7 Cell culture 
L929 mouse fibroblasts (ECACC-85011425, London, UK) were thawed and 
resuspended in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 
4.5 g/L glucose and L-glutamine, 1% penicillin/streptomycin and 10% foetal bovine 
serum (FBS; Life Technologies, Carlsbad, CA). Cells were grown using standard 
cell culture conditions (37°C, 5% CO2), harvested by trypsinisation and centrifuged 
at 1000 rpm before being resuspended in growth media (supplemented DMEM) for 
passaging or use at 90% confluence. 
 
2.2.8 Cell attachment assay 
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This protocol is adapted from Methods in Molecular Biology - Methods and Protocols 
- Extracellular Matrix Protocols Second Edition150. The attachment assay is modified 
for use on 12 mm cover slips in a 24-well plate. Instead of using Crystal Violet as a 
marker to determine the percentage of attached cells, samples are fixed and stained 
with DAPI in order to count the number of cells attached in each condition. The same 
cell density, incubation times and buffers are used as described in the protocol. 
All cell-related experiments were carried out in sterile conditions (with the use of 
sterile FN) in a laminar flow cabinet suitable for cell culture. PEA, PMA and glass 
coverslips were sterilised in UV for 20 minutes, coated with sterile supplied FN 
(20 µg/ml) for 1 hour, and, washed twice with PBS. Samples were then blocked with 
heat-denatured 1% BSA (Roche) in DPBS for 30 minutes at room temperature. 
During this period, cells were harvested, trypsinised and resuspended in complete 
growth medium (containing 10% FBS). The cell suspension was then transferred to 
a tube and incubated for 10 minutes at 37°C, 5% CO2. 
Cells were then seeded onto the surfaces at a seeding density of 8.5x104 cells/cm² 
(3.4x105 cells/ml) for 20 minutes at 37°C, 5% CO2. Surfaces were then rinsed twice 
with DPBS to remove cells that were not firmly attached, fixed with formaldehyde 
4% for 20 minutes at 4°C and rinsed three times with DPBS. 
Samples were then permeabilised using the triton X-100 based permeabilisation 
buffer in the following Table 4 and mounted with Vectashield® containing DAPI to 
stain the nuclei.  
 
Table 4: Permeabilisation buffer composition 
Reagent Amount (for 100 ml) 
Saccharose 10.3 g 
NaCl 0.292 g 
MgCl2 0.06 g 
Hepes 0.476 g 
Triton X-100 0.5 ml 
pH adjusted to 7.2 and filtered (0.22 µm filter) 
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Images were taken using an inverted epifluorescent microscope and the number of 
cells attached was determined using CellC, a program that was developed to count 
cells (in this case their nuclei)151. 
This experiment was also carried out with an extra blocking step in which the RGD 
cell binding and the PHSRN synergy sequence domains of FN were blocked. This 
was done using HFN7.1 (DHSB) and mAb1937 (Millipore) antibodies respectively. 
Samples coated with 20 µg/ml FN were further incubated for 1 hour with HFN7.1 
and/or mAb1937 at 14.6 µg/ml for a 1:1 antibody-FN ratio. Cell seeding, incubation, 
fixing and staining were all done in the same way. 
 
2.2.9 Early adhesion assay 
Samples (PEA, PMA and glass cover slips) were sterilized for 20 minutes using a 
UV lamp and then coated with FN at 2, 5, 10 and 20 µg/ml for 1 hour. Samples were 
then rinsed twice with DPBS and cells were seeded at 5x103 cells/cm2 
(2xss4 cells/ml) and cultured for 3 hours (37°C, 5% CO2). Triplicates were used for 
each condition. 
After washing, samples were fixed with formaldehyde 4% for 20 minutes at 4°C and 
rinsed three times before being stored in DPBS at 4°C until ready to be stained. 
 
Samples were then permeabilised using the same permeabilisation buffer 
previously described in Table 4, blocked for 30 minutes with 1% BSA (in DPBS), 
and, incubated for one hour using an antibody against vinculin hVIN-1 (in mouse; 
1:400 dilution; Sigma) to visualise FAs. Samples were then rinsed twice with 0.5% 
Tween20 (in DPBS) and incubated with a Cy3-conjugated anti-mouse secondary 
antibody (Cy3 anti-mouse; 1:200 dilution) for 1 hour in the dark. The secondary 
antibody was coupled with Phallacidin (1:100 dilution) which stains the actin 
cytoskeleton.  
Samples were then rinsed twice with 0.5% Tween20 (in DPBS) and mounted with 
Vectashield® (Vector laboratories, Inc.) with DAPI which stains the nuclei. 
Staining was then observed using an inverted epifluorescence microscope at 
different magnifications. Images were taken and merged using ImageJ in order to 
have cells with stained nuclei, actin and FAs. 
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2.2.10 Early adhesion with blocking 
In the case of cell adhesion after blocking specific FN domains, samples coated with 
20 µg/ml FN were further incubated for 1 hour with HFN7.1 and/or mAb1937 at 
14.6 µg/ml for a 1:1 antibody-FN ratio, to block the RGD and the synergy domains 
respectively. Antibodies were diluted in 1% BSA. Samples were coated with 
20 µg/ml of FN only. 
Cells were then seeded onto surfaces and samples were fixed and permeabilised 
just as described in the standard early adhesion assay. 
Due to the fact that the antibodies directed against the cell binding domain and 
synergy sequence (HFN7.1 and mAb1937 respectively) were produced in mouse 
just as the antibody used to stain vinculin (hVIN-1), the Zenon® labelling technology 
kit was used. 
The Zenon® technologies kit (Life technologies) is able to label small quantities of 
primary antibody with an incubation time of 10 minutes. They consist of labelled Fab 
fragments that bind to the Fc domain of the primary antibody thus eliminating the 
need for the secondary antibody. 
The following Figure 12 shows the principle of the Zenon® labelling technology.  
 
Figure 12: How Zenon® Labelling Technology works. Noncovalent labelling 
with Zenon® antibody labelling152. Labelled Fab fragments were incubated 
with the primary antibody of interest (in this case hVIN-1) and excess Fab 
fragments were bound to a nonspecific IgG provided with the kit. The Zenon® 
labelled antibody was then ready to be used with the samples. From Thermo 
Fisher Scientific152. 
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In this instance, the Zenon® kit was used to bind labelled Fab fragments to hVIN-1 
before incubating the antibody with the cells. 1 µl of hVIN-1 (1mg/ml) was diluted in 
190 µl of 1% BSA in DPBS. 5 µl of Alexa Fluor® 555 labelled Fab fragments 
(reagent ZA) was then added and incubated (5 minutes, RT) after which 5 µl of 
nonspecific IgG1 (reagent ZB) was added to complex unbound Fab fragments (5 
minutes, RT). 2 µl of Phallacidin was then added to stain the actin cytoskeleton. 
Samples were then incubated with this mixture for 1h at room temperature before 
being rinsed three times with 0.5% Tween20 in DPBS and mounted with 
Vectashield® containing DAPI.  
Staining was then observed using an inverted epifluorescent microscope at different 
magnifications (5x, 10x, 20x and 40x in dry conditions and 63x using immersion oil). 
Images were taken and merged using ImageJ in order to have cells with stained 
nuclei, actin and FAs. 
 
2.2.11 Focal adhesion quantification – focal adhesion analysis server 
In the case of the early adhesion assay (with and without blocking), images of 
vinculin staining taken at 63x magnification were analysed using the Focal Adhesion 
Analysis Server (FAAS) web tool153 (Figure 13). This webserver, hosted from the 
University of North Carolina at Chapel Hill, has been previously described in 
literature and is commonly used to analyse labelled FAs proteins in cells by 
measuring the number, size, area, intensity, and, distribution of FAs among other 
parameters154.  
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Figure 13: Focal Adhesion Analysis Server. Example of the different steps to 
identify and quantify FAs (in green). Images of the FAs and cell mask were 
uploaded to the server which converts them to binary images. FAs detected 
within the cell mask were then characterised (number, area, length… etc.). 
Scale bar: 50 µm. 
 
In order to determine if the FAAS produced reliable results a validation test was set 
up (Figure 14). Samples which represent cells and their FAs were created with 
known parameters such as ‘cell’ size, ‘FA’ size and ‘FA’ distance from the centre 
and from the edge of the ‘cell mask’. 
Several shapes of cells were used such as circles, triangles and squares of different 
sizes along with different sizes of FAs that are consistent with natural FA sizes. 
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The following figure represents different images submitted and analysed by the 
FAAS with known parameters. 
 
Figure 14: FAAS tool validation. From left to right: square, triangle and circle 
images submitted with “FAs” of different sizes and distances from the centre 
and edges of the shapes. With known values for size and distance we were 
able to assess to ability of the server to accurately characterise FAs. Scale 
bar: 50 µm. 
 
Once the tool was validated, images of vinculin and the corresponding actin 
cytoskeleton (mask) staining of cells for each condition were uploaded to the server 
and analysed.  
This data was used to establish the size distribution of the FAs and the ‘geometric 
moment of inertia’ for each condition. The geometric moment of inertia (I) is 
calculated based on FA size within the cell and the distance from the centre of the 
cell.  
 
 
Equation 2: 
𝑰 =  ∑ 𝒂𝒊. 𝒓𝒊
𝟐
𝑵
𝒊=𝟏
 
I: moment of inertia of each cell 
a: Area of focal adhesion (µm2) 
r: Distance of focal adhesion from centre (µm) 
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Five cells per condition were used for these experiments. Only FAs larger than 1 µm 
in length were taken into account in order to exclude focal complexes60, 155. 
 
2.2.12 Statistical analysis 
Two-way ANOVA was used for the comparison of the different groups using a 
Bonferroni post-test to compare all columns. Data is represented as mean ± SD and 
the differences between groups were considered significant for P<0.05. 
 
2.3 Results   
2.3.1 FN adsorption 
Once PEA and PMA were spun onto glass coverslips and coated with FN surface 
wettability was characterised by water contact angle (Figure 15), FN adsorption was 
characterised by AFM, immunostaining and micro BCA, and, domain availability was 
characterised by ELISA.  
Static, advancing and receding WCA were measured on polymers and on glass with 
different amounts of FN adsorbed on each surface.  
 
 
 
Figure 15: Comparison of water droplets on PEA, PMA and glass surfaces 
with no FN coating. Visible differences were noted between droplets on 
different surfaces. Water droplets on PMA were the most rounded compared 
to droplets on PEA and glass, which was the flattest, indicating varying 
degrees of hydrophobicity. 
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Depending on the hydrophobicity of the surface, the contact angle of the droplet 
differs. Angles are larger on polymers which are more hydrophobic surfaces 
compared to glass.  
The following Figure 16 shows static, advancing and receding contact angles along 
with hysteresis of PEA and PMA coated with FN. 
 
Figure 16: Water contact angle of PEA and PMA with 0, 2, 5, 10 and 20 µg/ml 
of FN. Static WCA was similar on both FN-coated polymers. Differences were 
observed in dynamic contact angles (advancing and receding) leading to 
differences in hysteresis. N = 9. 
 
The similar chemical composition of PEA and PMA is highlighted in the similarities 
in hydrophobicity with a SCA of approximately 75° on bare polymers and when 
coated with increasing amounts of FN. A similar trend is observed with the ACA with 
contact angles between 90-100° on both surfaces. A noticeable difference in 
receding contact angles was observed with a larger decrease in contact angle on 
PEA compared to PMA with increasing concentrations of FN. With no FN on 
surfaces, the RCA on both surfaces is ~30°. However, when FN is coated on the 
surface the RCA decreases to 7° on PEA as opposed to 24° on PMA. This translates 
to increased hysteresis on PEA compared to PMA. 
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AFM (Figure 17) and immunostaining (Figure 18) were used to observe the 
conformation of FN upon adsorption unto polymers. 
 
Figure 17: AFM representation of PEA and PMA coated with 20 µg/ml of FN 
for 10 minutes and 1 hour. The beginning of a FN network was seen after 10 
minutes on PEA with a fully formed network observed after 1 hour. On PMA, 
FN remains globular after 1 hour. Scale bar: 0.5 µm. 
 
Upon adsorption on PEA, FN has a network conformation that develops with time, 
as observed with AFM. After 10 minutes the protein absorbed begins forming 
networks and after 1 hour those networks are fully formed across the surface (Figure 
18). This is in contrast to PMA where FN remains in a globular conformation even 
after being adsorbed for 1 hour. 
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Figure 18: Immunostaining of FN on PEA (top) and PMA (bottom) at 2, 5, 10 
and 20 µg/ml after 1-hour coating. FN on PEA formed a network after 1 hour 
regardless of the concentration. Likewise, FN on PMA formed globules after 
1 hour for all concentrations used. Scale bar: 50 µm. 
 
Immunostaining confirmed that FN has a network conformation on PEA whereas it 
forms aggregates on PMA for all concentrations of FN on the surface. 
FN adsorbs more onto PEA compared to PMA for a small amount of coating (i.e. 
1 µg/ml) with protein surface densities of 200 and 30 ng/cm2 respectively (Figure 19 
A). However, for the standard coating concentration of 20 µg/ml, no significant 
differences are visible with protein surface densities of 550 – 750 ng/cm2.  
 
 
Figure 19: FN adsorption and domain availability on PEA and PMA coated 
with 1 and 20 µg/ml of FN for 1 hour. (A) Surface density of FN on PEA and 
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PMA. (B) Availability of RGD and PHSRN domains of FN. N = 9, ***p<0.001. 
From Vanterpool, F. et al. 20145. 
 
In order to analyse the exposure and availability of integrin binding domains after 
adsorption of FN onto polymers, an ELISA using monoclonal antibodies directed 
against the HFN7.1 cell binding domain and the PHSRN synergy sequence was 
carried out (Figure 19 B). At a low concentration (1 µg/ml) of FN, the binding of both 
antibodies is higher on PMA indicating a higher biological activity of the protein. 
However, an increase in the concentration to its standard 20 µg/ml results in similar 
availability of the RGD domain on both polymers whereas there is significantly 
higher availability of the PHSRN synergy sequence on PEA compared to PMA.  
 
2.3.2 Cell attachment and adhesion 
Cell culture experiments with L929 mouse fibroblasts were carried out to assess 
short-term attachment and adhesion on FN coated polymers. This was done using 
a standard 20-minute attachment protocol and 3-hour early adhesion protocol.  
When cells attach for 20 minutes to surfaces coated with 20 µg/ml of FN solution 
(Figure 20 A), over 90% of cells initially seeded remain attached after several 
washes with PBS, which is the same amount as FN coated surfaces that were 
washed. When surfaces were not coated with FN however cells did not attach to the 
surface, highlighting the importance of FN for early cell attachment.  
In order to study cellular response to FN-coated polymers, 3-hour adhesion 
experiments were carried out with FN at 2, 5, 10 and 20 µg/ml in serum-free 
conditions. A low seeding density was used (5000 cells/cm2) in order to avoid any 
cell-cell interactions and focus solely on cell-FN-material interactions. L929 
fibroblasts spread on all surfaces with FN and remained rounded on surfaces with 
no FN (Figure 20 C). Cells maintained a consistent size on both surfaces of 1000-
1500 µm2 when coated with 2, 5 and 10 µg/ml of FN whereas for 20 µg/ml cells were 
significantly larger on PEA, ~ 2000 µm2, compared to PMA, ~ 1400 µm2 (Figure 20 
B). Moreover, for the minimum concentration (2 µg/ml), the actin cytoskeleton was 
not as developed with stress fibres only visible at the periphery. This is in contrast 
with 20 µg/ml where stress fibres are visible across the cells, more notably on PEA. 
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Figure 20: Attachment and spreading on L929 mouse fibroblasts on PEA and 
PMA coated with various concentrations of FN. (A) Attachment for 20 minutes 
of L929 on PEA and PMA coated with 20 µg/ml of FN. Cells attach firmly to 
both PEA and PMA after 20 minutes once FN in present on the surface 
whereas cells don’t attach to the bare polymers without FN. (B) Cell area after 
3 h adhesion on PEA and PMA coated with 2, 5, 10 and 20 µg/ml FN solution 
for 1 h. Cell area remains constant for cells on PEA and PMA coated with 
lower concentrations of FN (2 – 10 µg/ml) whereas cells are  significantly 
larger on PEA compared to PMA when coated with 20 µg/ml of FN.(C) 
Representative images of L929 cells on PEA (top) and PMA (bottom) coated 
with 0, 2, 5, 10 and 20 µg/ml of FN (noted: FN0, FN2, FN5, FN10 and FN20). 
Samples are stained for actin (green), vinculin (red) and nucleus (blue). 
**p<0.01. Scale bar: 50 µm. (A and B from Vanterpool, F. et al. 20145). 
 
FAs were more developed with increasing FN concentrations on both polymers, 
located at the end of stress fibres (Figure 21 A). To assess FA maturity, the length 
of the major axis of focal plaques were quantified. Vinculin images were used and 
processed as previously described (Figure 13) and focal complexes inferior to 1 µm 
in length also known as focal points were discarded from analysis.  
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Cells on PMA presented a higher percentage of shorter FAs(35-40%) compared to 
cells on PMA (25-30%). Furthermore, the percentage of larger FA (≥ 3 µm) was 
slightly higher on PEA compared to PMA (Figure 21 B). 
 
 
Figure 21: FA organisation on PEA and PMA coated with 2, 5, 10 and 
20 µg/ml of FN solution. (A) Representative inverted binary representation of 
FAs. (B) Size distribution of FAs quantified with the FA analysis server. n = 
5, scale bar: 50 µm. From Vanterpool, F. et al. 20145. 
 
The median of FA size (Figure 22 A) increased significantly with increasing amounts 
of FN for cells on PEA whereas they remained constant for cells on PMA. 
Essentially, the slope for PEA (0.0101x + 0.00203) is statistically different from 0 
(p<0.05) whereas the slope for PMA was not.  
The area moment of inertia (Equation 2) which assess the distribution of points (in 
this case FAs) around a central axis (in this case the central axis of the cell) was 
used to analyse FAs on PEA and PMA with varying concentrations of FN (Figure 22 
B). PEA presented a significantly higher moment of inertia (4x104 µm2) compared 
to PMA (2x104 µm2). This being the result of increased cell size, thus increasing the 
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distance from the centre of the cell to the edges (where FAs are most present), as 
well as FAs being larger on PEA.  
 
 
Figure 22: Assessment of FAs. (A) Median of FA size on PEA and PMA 
coated with 2, 5, 10 and 20 µg/ml of FN solution. (B) Moment of inertia for 
the distribution of FAs. **p<0.01. 
 
 
2.3.3 Cell adhesion after blocking RGD and/or synergy domains of FN 
Early adhesion (3 hours) as well as attachment (20 minutes) experiments were 
carried out with an extra step during which the RGD cell binding domain and/or the 
PHSRN synergy sequence of FN was blocked using HFN7.1 and mAb1937 
antibodies respectively.  
Though cells attached the same on polymers in normal conditions (Figure 23 A), 
FAs were larger in both average area and number on PEA (Figure 23 B and C). Cell 
attachment is inhibited on both polymers when the RGD domain is blocked (H). This 
blocking also results in decrease in the number of FAs and FA area, especially for 
cells on PMA. Blocking the synergy sequence (m) has no effect on cell attachment, 
however, the number of FAs as well as their size is significantly decreased on PEA 
with no detectable FA on PMA. The use of both HFN7.1 and mAb1937 antibodies 
drastically reduced the number and size of FAs on PEA and therefore the moment 
of inertia. No FAs were detected on PMA in this instance. 
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Figure 23: Cell attachment and FA quantification after blocking RGD or 
synergy domains of FN with HFN7.1 and mAb1937. (Ø denotes no 
antibodies; H denotes the use of HFN7.1; m denotes the use of mAb197; 
H+m denotes the use of both HFN7.1 and mAb1937). (A) Cell attachment 
shows that cells that bind equally on PEA and PMA when no antibodies are 
used attach to the polymer surfaces differently especially when antibodies 
are used together (H+m). (B) and (C) FA area and size shows that cells on 
PEA have more and larger FAs in standard conditions whereas adding 
antibodies significantly diminishes the size and amount of FA. (D) Moment of 
inertia reflects the results of FA area and count. **p<0.01, ***p<0.001. From 
Vanterpool, F. et al. 20145. 
 
 
 
2.4 Discussion 
2.4.1 Surface chemistry and FN adsorption 
It is well known that surface chemistry influences the adsorption of FN in terms of 
the amount of protein and its conformation on the polymeric surface. García et al. 
showed that using hydrophilic OH-SAM lead to very little changes to the 
conformation of FN or the recombinant FN-III7-10 fragment upon adsorption whereas 
the use of hydrophobic CH3-SAM lead to significant changes55, 147. This surface 
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modulation resulted in modified biological activity of FN leading to changes in 
integrin binding, FA organisation and intracellular signalling pathways which in turn 
dictated various degrees of cell differentiation147, 156, 157.  
PEA and PMA polymers are hydrophobic surfaces with similar static and receding 
water contact angles of approximately 75° and 35° respectively. The advancing 
contact angle, slightly higher on PEA compared to PMA (100° on PEA versus 90° 
on PMA), leads to increased hysteresis indicating higher surface mobility.  
 
2.4.2 FN conformation and integrin binding domain availability 
These results confirm that the conformation as well as the distribution of FN can be 
controlled using surfaces with very comparable physico-chemical properties. The 
differences in protein conformation on PEA and PMA has far reaching implications 
at a molecular scale and is translated to differences in the availability of the FNIII9-
10 integrin binding domain. With the same amount of FN adsorbed after coating with 
the standard 20 µg/ml (600-700 ng/cm2 measured on the surface), the RGD domain 
was equally available on both polymers. However, the same could not be said for 
the PHSRN synergy sequence located on the FNIII9 domain which was more 
exposed on PEA compared to PMA (Figure 19B). This has significant consequences 
in relation to integrin binding. Previous studies have shown that both the RGD 
domain (FNIII10) and synergy sequence (FNIII9) are needed in order to bind integrin 
α5β150, 158. Furthermore, blocking both RGD and PHSRN sequences lead to 
complete inhibition of attachment on PMA versus partial attachment of cells on PEA 
(Figure 23 A). This indicates that cell attachment on FN-coated PEA was mediated 
preferably via PHSRN/α5β1 as opposed to cells that attached onto PMA via the 
RGD/αvβ3 FN domain/integrin combination. 
 
2.4.3 Biological response – focal adhesion formation 
The biological response observed by cell attachment and FAformation are direct 
responses to cells being presented to FN which itself is modulated by the underlying 
material surfaces68. Vinculin was used as a marker of FA as it is one of the main 
proteins recruited at the site of adhesions (Figure 6) mediated by α5β1 and αvβ3 
integrins159. Furthermore, vinculin is necessary for myosin contractility-dependent 
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adhesion strength as well as the coupling of cell area with traction force160. A direct 
relationship exists between the formation (as well as size) of FAs and the 
mechanical properties of the external microenvironment of the cell. It has been well 
documented that stiff substrates, along with the application of certain stresses and 
strains, contribute to the development of large FAs. Contrarily, soft substrates with 
little strain and stress favour the formation of much smaller FAs known as focal 
complexes66, 161.  
As a side-note, nanotopography (such as nanopillars, nanopits and nanogrooves) 
has also been shown to have an effect on the size and direction of FAs with integrin 
clustering and cytoskeleton organisation162, 163.  
This study shows that the conformation and distribution of FN on surface materials 
with similar properties can be used as a tool to dictate FA organisation. The globular 
FN on PMA allowed for the formation of smaller FAs (focal complexes) whereas the 
fibrillar conformation of FN on PEA allowed for longer and more developed 
adhesions (Figure 21A). This was shown to be independent of the amount of FN 
used to coat the surfaces as the trend was observed when coating with low amounts 
of FN (2 µg/ml) all the way to 20 µg/ml FN. Moreover, the size distribution of FAs 
remained constant on PMA with increasing amounts of FN. The same could not be 
said of the FA distribution in cells on PEA where the fraction of large FAs increased 
with increasing concentrations of FN. Although it is a crude representation, this can 
be observed by looking at the median size of FAs on PEA and PMA with increasing 
amounts of FN (Figure 22A).  
These larger FAs on PEA resulted in cells being more spread compared to PMA 
(Figure 20B). FA size as well as cell size both contributed to higher values of 
moment of inertia of cells on PEA compared to PMA. Previous studies have shown 
that cells apply an approximate stress of ~5.5 nN/µm on substrates65. This suggests 
that cells are able exert larger forces on FN when in a fibrillar conformation on PEA 
than on FN in a globular conformation on PMA, surfaces which are both sensed as 
stiff by the cell due to their Young’s moduli (Table 8) which are much higher than 
physiologically ‘soft’ tissue such as fat and muscle164.  
 
2.4.4 Biological response – blocking integrin binding domains 
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When FNIII9 and FNIII10 domains of FN were blocked with mAb1937 and HFN7.1 
monoclonal antibodies respectively, results corroborated the idea that PEA and 
PMA can influence biological response. When FNIII10 was blocked, thus inhibiting 
the RGD domain availability, a drastic reduction in cell attachment was observed on 
both surfaces. When FNIII9 was blocked, inhibiting the availability of the PHSRN 
synergy sequence, cell attachment was not affected (Figure 23A). This shows that 
when the synergy sequence is unavailable, cells are still capable of adhering to the 
FN irrespective of conformation using the equally available RGD domain via the 
αvβ3 and not the α5β1 integrin. Blocking also had a clear effect on FA formation with 
a significantly lower amount of FAs on PMA after blocking with either antibody 
compared to PEA where FAs, albeit smaller than normal, were found. Cells were 
still able to adhere to fibrillar FN on PEA via other biding domains on the extended 
proteins but not on PMA due to the fact that the protein remains in a globular 
conformation, with no other available binding domains.  
The following (Figure 24) is a summary of this model in which an underlying material 
surface can influence the conformation of FN, thus the availability of integrin binding 
domains that in turn directs cell behaviour. 
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Figure 24: Mechanistic model for the material-based modulation of FN 
conformation. (A) FN monomer with binding domains of integrins and other 
ECM proteins. The main integrin binding domain of FN (FNIII9-10) highlighting 
the RGD and PHSRN sequences in yellow. (B) FNII9-10 fragment of FN with 
binding sited of HFN7.1 and mAb1937 antibodies which block the RGD domain 
on FNIII9 and the PHSRN synergy sequence on FNIII10 respectively. (C) FN 
takes on a globular conformation on PMA, therefore hiding the integrin binding 
sites which is accentuated by blocking the RGD and PHSRN sequences. (D) 
When on PEA FN extends and takes on a fibrillar conformation, exposing more 
integrin binding sites even when the RGD and PHSRN sequences are blocked 
leading to more possibilities for cell interactions. Adapted from Vanterpool, F. 
et al. 20145. 
 
2.5 Conclusions 
It’s been demonstrated that it is possible to modulate FN conformation via material 
surfaces that have similar physico-chemical properties. The difference between 
PEA and PMA being only one methyl group in the side chain with both having 
comparable wettability characteristics. This however translates to noticeable 
differences in the organisation of FN upon adsorption with nanonetwork structures 
forms on PEA whereas globules form on PMA. Consequently, the extended 
conformation of FN on PEA led to an increase in the availability of integrin binding 
domains, more notably the PHSRN synergy sequence located on the FN-III9 repeat. 
This specific difference on FN-coated PEA led to a higher distribution of larger FAs 
compared to smaller focal points noticed on PMA. The differences in FN 
conformation were confirmed by blocking the FN-III9-10 domain with monoclonal 
antibodies which showed that FAs were maintained on PEA but not on PMA. These 
results show that cells are susceptible to FN organisation and domain availability on 
polymeric surfaces independent of the underlying physico-chemical properties of 
the materials. 
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3  Focal adhesion formation and cell 
migration in DU145 human prostate cancer 
cells  
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3.1 Introduction 
3.1.1 Prostate cancer  
Once considered a very rare disease in the 19th century, prostate cancer has 
become the most common form of cancer in men. In the US and Europe 
respectively, it is the second and third most common cause of death 165, 166. It 
consists in the formation of tumorous cells in the prostate, with various types of 
prostate cancer existing depending on the tissue and cell type where it originated. 
The most common type being acinar adenocarcinomas which develops in the gland 
cells that line the prostate. Other forms of prostate cancer include ductal 
adenocarcinomas (cells that line the tubes of the prostate gland), and urothelial 
cancer (cells within the urethra)167.  
 
3.1.2 Current and potential treatments of prostate cancer 
One of the most common treatments for prostate cancer is hormone therapy. Male 
hormones known as androgens are needed for the growth and function of the 
healthy prostate gland168. However, these hormones also promote the growth of 
cancerous prostate cells via their androgen receptors (AR). This is the main 
therapeutic target in prostate cancer treatment due to the fact that studies have 
shown that AR is necessary for cell viability, proliferation and invasion169-171. 
Hormone therapy, also known as androgen suppression/deprivation therapy 
consists of inhibiting the production and utilisation of androgens172. This is done by 
inhibiting production of androgens by the testicles (medical or surgical castration), 
blocking the action of androgens (antiandrogens that competitively bind AR), or, 
blocking the production of androgens throughout the body (blocking production in 
adrenal glands and cancer cells). These treatments are carried out in parallel with 
standard chemotherapy and radiation and it has been shown to be more effective 
than simply removing the prostate or testicles surgically173. 
Prostate cancers, however, tend to develop resistance to this form of treatment and 
become less sensitive to androgen depletion causing a relapse in cancer 
progression174, 175. Although many drugs such as Enzalutamide, Cabaitaxel and 
Radium-223 have recently been developed to treat castration resistant treatments, 
they fail to effectively halt cancer progression and metastasis.  
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3.1.3 Choice of DU145 cell line 
DU145 is a classical epithelial prostate cancer cell line and is derived from a 
metastatic site in the brain of a 69 year old Caucasian male 176. It is considered to 
have moderate metastatic potential compared to PC3 which has a high metastatic 
potential. Many studies have been done using this cell line due to the fact that it is 
reportedly not hormone sensitive but has shown to interact with ECM protein 
including FN, more notably via the α5β1 and αvβ3 integrins. Several studies have 
used the PHSCN, a competitive inhibitor of the PHSRN sequence, in order to 
supress metastasis in this cell line48, 49, 177, 178. Interestingly, a study by Livant et al. 
suggested that the PHSRN synergy sequence without the RGD sequence is 
sufficient to induce invasion of DU145 cells whereas the same could not be said of 
the opposite scenario49.  
Our studies have shown that upon adsorption to PEA and PMA, FN takes on fibrillar 
and globular conformations respectively where the extended fibrillar form on PEA 
confers higher availability of the PHSRN sequence compared to PMA5 (Figure 19B). 
Seeing that the DU145 is particularly sensitive to PHSRN, using material-based 
platforms that can affect that sequence’s availability could prove useful to study its 
importance in cancer cell motility. 
 
3.1.4 Hypothesis and experimental aims 
We hypothesise that differences in FN conformation on PEA and PMA have an 
impact on human prostate cancer cell attachment, traction and migration via the 
differential expressions of intracellular proteins involved in FA formation such as 
FAK. The aims of this study are therefore to use well-defined and characterised 
polymer systems with known effects on FN upon adsorption to characterise cancer 
cell proliferation, migration, traction, and drug resistance and to elucidate the 
underlying mechanisms involved in these processes. 
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3.2 Materials and methods 
3.2.1 Cell culture  
DU145 human prostate cancer cells (ATCC – HTB81) were thawed and 
resuspended in Minimum Essential Media Alpha growth medium (MEM Alpha) 
supplemented with GlutaMAXTM, 1% P/S, and, 10% FBS. Cells were grown using 
standard cell culture conditions (37°C, 5% CO2), harvested by trypsinisation and 
centrifuged at 1000 rpm before being resuspended in growth media (supplemented 
MEM Alpha) for passaging or use at 90% confluence. 
In order to better characterize the DU145 human prostate cancer cell line (ATCC – 
HTB81), a growth assay was carried out. This was done using MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and alamarBlue® assays, 
both of which assess cell viability by measuring colorimetric changes proportional 
to cell activity.  
 
3.2.2 DU145 growth  
3.2.2.1 MTT assay 
Cells use the NAD(P)H-dependent oxidoreductase enzymes to reduce MTT, a 
tetrazolium dye, to formazan, a water-insoluble purple product179. 
In this experiment, cells were seeded into 96-well plates at 500 and 5,000 cells/well 
(1.6x103 and 1.6x104 cells/cm2 respectively). Every day for 7 days, 20 µl of MTT 
was added to a row in the 96-well plate and incubated at 37ºC for 5 hours. The 
medium with MTT was then carefully removed without removing the formed crystals 
and replaced with 110 µl of DMSO in order to dissolve the formazan crystals for 15 
minutes at 37ºC. The solution was then transferred to a new plate and absorbance 
was read at 570 nm using a Multiskan Ascent, model no. 354 plate reader (Thermo 
Labsystems). 
 
3.2.2.2 AlamarBlue® assay 
Similarly to MTT cells reduce Resazurin, a blue non-toxic active ingredient in 
alamarBlue®, to resofurin, a fluorescent red compound180. 
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This experiment was carried out on tissue culture plastic (TCP) as well as on PEA, 
PMA and glass. Coverslips were sterilised by UV and coated with FN or just DPBS 
for 1 hour before being rinsed twice and transferred to a 24-well plate.  
In the case of TCP, cells were seeded in a 96-well plate at different seeding densities 
ranging from 1.5x103 to 6x105 cells/cm2 in order to determine an optimal seeding 
density for growth on polymers. Cells were subsequently seeded onto PEA, PMA, 
and, glass at 1.5x103 and 1.5x104 cells/cm2. In both instances cells were seeded 
and incubated in media without FBS for the first 3 hours, after which, the media was 
replaced with fresh media containing 10% FBS and incubated overnight. 
AlamarBlue® was then added (10% of the total volume per well) and samples were 
incubated for 4h at 37°C, 5% CO2. The media was then transferred to a black, flat-
bottom 96-well plate and fluorescence was measured using the Tecan® M200 pro 
plate reader, with an excitation wavelength at 560 nm and an emission wavelength 
at 590 nm. This was done over the course of one week. Fluorescence was 
measured using constant gain at 60 throughout. 
 
3.2.3 Cytotoxicity (docetaxel and PND-1186) 
For both drugs, cytotoxic studies were first carried out in a 96-well to determine the 
IC50 from a wide range of concentrations. Cells were seeded at 5x103 cells per well 
(1.5x104 cells/cm2) and incubated overnight. Media was then removed and replaced 
with media containing 10-4, to 103 nM of docetaxel181 or PND-1186. After 72h, the 
viability of cells was measured using alamarBlue®. 
Cytotoxicity of docetaxel alone was measured on PEA, PMA and glass coated with 
FN using the same seeding density (1.5x104 cells/cm2) and viability was also 
measured using alamarBlue®. 
Fluorescence was measured using the Tecan® M200 pro plate reader, with an 
excitation wavelength at 560 nm and an emission wavelength at 590 nm. 
 
3.2.4 Cell attachment assay 
PEA, PMA and glass coverslips were sterilised in UV for 20 minutes, coated with 
FN (20 µg/ml) for 1 hour, and, washed twice with PBS. Samples were then blocked 
with heat-denatured 1% BSA (Roche) in DPBS for 30 minutes at room temperature. 
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During this period, cells were harvested, trypsinised and resuspended in complete 
growth medium (containing 10% FBS). The cell suspension was then transferred to 
a tube and incubated for 10 minutes at 37°C, 5% CO2. 
Cells were then seeded onto the surfaces at a seeding density of 8.5x104 cells/cm² 
(3.4x105 cells/ml) for 20 minutes at 37°C, 5% CO2. Surfaces were then rinsed twice 
with DPBS to remove cells that were not firmly attached, fixed with formaldehyde 
4% for 20 minutes at 4°C and rinsed three times with DPBS. 
Samples were then permeabilised using the triton X-100 based permeabilisation 
buffer in the following table and mounted with Vectashield® containing DAPI to stain 
the nuclei.  
This was also carried out with an extra blocking step with the use of HFN7.1 and 
mAb1937 as previously described. 
 
3.2.5 Cell attachment assay with PND-1186 
For experiments in which FAK phosphorylation was inhibited, PND-1186, a potent 
FAK inhibitor currently in phase 1 clinical trials for metastatic cancer, was used. This 
drug reported to have a cellular IC50 of ~100 nM in breast carcinoma cells as 
determined by anti-phospho-specific immunoblotting to FAK Tyr-397101 and has 
shown to supress cell migration. 
Samples were prepared in the same way as in the standard attachment assay 
(Chapter 2). However, cells were harvested and resuspended in growth media with 
0, 150 or 1500 nM of PND-1186 and were incubated in tubes with gentle agitation 
for 1 hour. Concentrations of 0, 150 and 1500 nM of PND-1186 were chosen to have 
cells in normal conditions with no drug, cells with the approximate reported IC50 
value and cells with a 10-fold increase of drug concentration. Cells were then 
seeded onto surfaces, incubated, rinsed, fixed and imaged in the same way. 
 
 
 
3.2.6 Early adhesion assay  
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Samples (PEA, PMA and glass cover slips) were sterilized for 20 minutes using a 
UV lamp and then coated with FN at 2, 5, 10 and 20 µg/ml for 1 hour. Samples were 
then rinsed twice with DPBS and cells were seeded at 5x103 cells/cm2 
(2x104 cells/ml) and cultured for 3 hours (37°C, 5% CO2). Triplicates were used for 
each condition. 
After washing, samples were fixed with formaldehyde 4% for 20 minutes at 4°C and 
rinsed three times before being stored in DPBS at 4°C until ready to be stained. 
Samples were then permeabilised, blocked for 30 minutes with 1% BSA (in DPBS), 
and, incubated for one hour using an antibody against vinculin hVIN-1 (in mouse; 
1:400 dilution; Sigma). Samples were then rinsed twice with 0.5% Tween20 (in 
DPBS) and incubated with a Cy3-conjugated anti-mouse secondary antibody (Cy3 
anti-mouse; 1:200 dilution) for 1 hour in the dark. The secondary antibody was 
coupled with Phallacidin (1:100 dilution) which stains the actin cytoskeleton.  
Samples were then rinsed twice with 0.5% Tween20 (in DPBS) and mounted with 
Vectashield® (Vector laboratories, Inc.) with DAPI which stains the nuclei. 
Staining was then observed using a Zeiss Z1 Observer inverted epifluorescence 
microscope at different magnifications. Images were taken and merged using 
ImageJ to have cells with stained nuclei, actin and FAs. 
In the case of early adhesion with blocking, an extra step was added after FN coating 
during which the RGD and PHSRN domains were blocked with HFN7.1 and 
mAb1937 antibodies respectively at 14.6 µg/ml for a 1:1 antibody-FN ratio for 1h at 
room temperature. Cell seeding, rinsing and fixing were done in the same way as 
the standard early adhesion assay. The Zenon® kit was used as described in Figure 
12 to label hVIN-1 anti-vinculin antibody before incubating with cells. Staining was 
observed with an inverted epifluorescent microscope. Images were taken at 63x 
magnification with immersion oil and FAswere analysed using the FA analysis 
server. 
 
 
3.2.7 Focal adhesion quantification 
Images of vinculin and actin staining were analysed using the FA analysis server 
web tool as previously described in Figure 13. A total of 30-45 cells per condition 
 61 
 
were analysed. An R script was therefore developed with the help of Ross Gurden 
of the Centre for Cell Engineering (CCE), part of the Institute of Molecular, Cells and 
Systems Biology of Glasgow University to process the output data of the FAAS. This 
script was used to collect data on cell size, and FA parameters for FAs larger than 
1 µm in length (anything less than 1 µm is characterised as a focal complex or focal 
point182) such as: FA count, size, area, distance from centre, distance from the edge 
of the cell and calculate the area moment of inertia (Equation 2) of each cell and 
output the mean, standard deviation and median of FA parameters per condition. 
 
3.2.8 Wound healing assay 
PEA, PMA and glass coverslips were coated with 20 µg/ml of FN for 1h, rinsed with 
PBS and left to dry. Ibidi® inserts were then placed on coverslips. DU145 cells were 
harvested, resuspended in media containing no FBS and seeded in insert wells at 
70x103 cells/ml for a confluent layer of cells. After 2h of seeding, the media in each 
well was replaced with media containing PND-1186 for an extra hour.  
 
After 1h, inserts were removed and wells were filled with media containing 2% FBS 
with no drug, 100 nM or 1000 nM of PND-1186. Images were then taken with the 
EVOS FL Auto automated epifluorescent microscope (Life Technologies) every 15 
minutes for 20 hours. 
 
3.2.9 FAK phosphorylation inhibition with PND-1186 
Wound healing assay was carried out with in the same way as previously described 
with 0 nM, 150 nM and 1500 nM of PND-1186. 
 
 
3.2.10 Single cell traction force microscopy (CTFM) 
The use of a polyacrylamide hydrogel containing fluorescent beads is a common 
method used in CTFM. Due to the inert properties of PAA, the hydrogel must be 
treated to allow cell adhesion and traction. This is usually done by functionalising 
the hydrogel using reagents such as sulfo-SANPAH to bind ECM proteins183 or by 
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coating the surface with maleic anhydride copolymers that can bind ECM 
proteins184. Here we engineer a system of PEA and PMA coated hydrogels in order 
to study the effect of FN conformation on cell traction. 
 
3.2.10.1 Passivation of coverslips with Sigmacote® 
Glass coverslips (32mm ø) were placed in an ultrasonic bath for 30 min and rinsed 
twice with water. Coverslips were then placed in an ultrasonic bath for 30 min with 
99% ethanol and rinsed twice with water. 
Coverslips were then cleaned for 10 min using an RCA solution (H2O : H2O2 medical 
grade 35% : NH3 p.a. 28%; 5 : 1 : 1) heated to 60°C before being rinsed twice with 
water and dried with a nitrogen flow (N2). 
Coverslips were then individually submerged in Sigmacote® (Sigma-Aldrich, Lot# 
SLBF4357V) solution (<5 sec) and left to dry at room temperature. In order to 
remove impurities, coverslips were then placed in an ultrasonic bath with 99% 
ethanol for 15 min and then dried with N2. Coverslips are then rinsed and stored in 
water at 4°C until ready to use. 
 
3.2.10.2 Acrylsilinisation 
Glass coverslips (22mm ø) were cleaned using the ultrasonic bath and RCA solution 
in the same way as described above. 
Acrylsilane solution was prepared with 94.8% EtOH p.a., 4.74% H2O and 0.44% 
acrylsilane. Coverslips were submerged in acrylsilane solution for 2 h, rinsed with 
ethanol and dried with N2. Samples were then tempered for 1h at 120°C and stored 
at 4°C until ready to use. 
 
3.2.10.3 Gel preparation 
PAA gels were prepared at 9 kPa stiffness with a mixture of acrylamide (AAm – 
monomer), bis-acrylamide (BisAAm – cross-linker), tetramethylethylendiamin 
(TEMED - accelerator), ammonium persulfate (APS – initiator) and Fluoresbrite 
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Microspheres (0.5 µm). The following Table 5 shows the amount of each ingredient 
added for the gels. 
 
Table 5: Gel preparation in order of addition 
Reagent Concentration (w/w) Quantity (µl) 
AAm 30% 60 
BisAAm 2% 60 
H2O (degassed) - 256 
Microspheres - 20 
TEMED 1.5% 20 
APS 5% 4 
 
The APS (initiator) was added last and the solution was vortexed briefly to mix 
everything together before pipetting 20 µl of the gel solution onto sigmacote 
coverslips. Acrylsilanised coverslips were then placed on top and left for 20 minutes 
until gels were polymerised. The following Figure 25 represents this process. 
 
 
Figure 25: PAA gel preparation. Gels were prepared systematically on 
acrylsilanised coverslips with the use of a hydrophobic coverslip coated with 
Sigmacote® to maintain a flat surface. 
 
After polymerisation, gels were left in H2O for half an hour to allow them to swell. 
Gels were then either left in H2O and stored at 4°C until ready to use (wet conditions) 
or vacuum dried at room temperature for 45 mins (dry conditions) to be used 
immediately. 
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3.2.10.4 PEA and PMA polymer preparation 
Polymers were prepared just as described in previous reports. For this experiment, 
however, PEA and PMA were prepared at 1% w/v in order to have a layer of polymer 
as thin as possible to spin coat on top of the PAA hydrogel.  
The thickness of the polymer layer was measured by spin coating onto glass 
coverslips and after drying, a scratch was made with a needle on the surface of the 
polymer and measured by AFM (tapping mode). This was done for different spin 
coating speeds in order to determine an optimal speed for polymer layers as thin 
and as homogeneous as possible. 
 
3.2.10.5 Polymer-coating of PAA hydrogels 
Polymers were coated onto hydrogels with the optimised spin coating conditions 
listed in the table below:  
 
Table 6: Traction force microscopy spin coating parameters  
Time 30 seconds 
Speed 4000 rpm 
Acceleration 200 rpm/sec 
 
This was done in both dry and wet conditions. For wet conditions, hydrogels were 
spun at 500 rpm for 7.5 seconds (with an acceleration of 750 rpm/sec) to remove 
any drops of water on the surface of the hydrogel before adding the polymer 
solution. 
Excess toluene was extracted by placing samples at 40ºC under vacuum for at least 
4 hours. In the case of wet conditions, toluene was extracted in a humid environment 
(wet paper towels were placed alongside samples to prevent drying while extracting 
toluene). 
After extraction of toluene, polymer coated hydrogels were sterilized for 30 min 
using a UV lamp, covered with MilliQ water, and stored at 4°C until ready to use (no 
longer than 24h). 
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3.2.10.6 Force spectroscopy 
Mechanical properties of polymers and PAA hydrogel as well as PAA coated with 
poly(styrene-alt-maleic anhydride) (PSMA), PEA and PMA was measured by force 
spectroscopy. PSMA is a commonly used maleic anhydride copolymer and was 
used in this study as a control. Force spectroscopy measurements were carried out 
using the Nanowizard 3 AFM from JPK in immersed conditions.  
 
Parameters of the cantilevers and tips used are listed in the table below. 
 
Table 7: Force spectroscopy parameters 
 PEA PMA PAA 
PAA+ 
PEA 
PAA+ 
PMA 
PAA+ 
PSMA 
Spring constant 
[N/m] 
3 3 0.1 – 0.3 
0.15 – 
0.35 
0.11 – 
0.37 
0.11 – 
0.2 
Sensitivity 
[nm/V] 
26.88 26.88 25 – 41 25 – 38 27 – 34 25 – 40 
Bead radius 
[µm] 
10 10 5 5 5 5 
Setpoint [nN] 150 150 7.813 7.954 8.58 9.889 
Indentation 
Depth for fitting 
[µm] 
0.1 0.1 0.2 0.2 0.2 0.2 
Velocity [µm/s] 2.5 2.5 1 1 1 1 
 
 
3.2.10.7 Bead displacement and traction force measurements 
Polymer-coated hydrogels were rinsed with PBS, coated with 20 µg/ml of FN for 30 
min at 37°C, and rinsed twice with PBS. 
DU145 human prostate cancer cells (grown in MEM-alpha media containing 10% 
FBS, 1% P/S and 1% glutamine), were harvested by trypsinisation, counted and 
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seeded onto hydrogels at a seeding density of 2000 cells/cm2 (in order to observe 
individual cells) for 2 hours. 
Cells were then observed using the Axio Observer Z1 epifluorescent microscope at 
40x magnification using phase contrast (to observe cells) and GFP fluorescent 
channel to observe microbeads (Figure 26). 
Images of individual cells were taken as well as the underlying fluorescent 
microbeads structure. This was identified as the “contracted” form of the gel. Once 
images were taken, growth media was removed and cells were detached using 
trypsin. PBS was then added to keep gels completely hydrated. Images of 
fluorescent microbeads in the same areas, where cells once were, were taken in 
order to obtain a reference or “relaxed” form of the gel to compare.  
 
 
Figure 26: Obtaining images. Images of cells were taken using phase 
contrast and the underlying microbeads structure was taken using GFP 
fluorescent channel before and after removing cells (contracted and relaxed 
states respectively). Scale bar: 50 µm. 
 
Images were then processed using Fiji (ImageJ v. 1.51k) in order to combine the 
compressed and relaxed state of the gel into a stack and correct for any slight x-y 
shift that could have occurred during the removal of cells. Bead displacement is then 
determined using a script in MATLAB able to identify small changes in the 
microbeads’ positions and determine a displacement field (displacement of 
beads)184-186. Knowing the mechanical properties of the gel (Young’s modulus and 
Poisson ratio), this is then converted into a traction field (forces exerted by the cell 
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on the gel) by the Fourier Transform Cell Traction Force Microscopy (FT-CTFM)187, 
188 or via in-house finite element modelling (Figure 27). 
 
 
Figure 27: Traction force analysis. (A) Phase contrast image of the cell 
converted to (B) a cell mask. Fluorescent channels of beads were used to 
determine the (C) displacement field of microbeads and converted it to (D) 
traction field within the cell. 
 
For these measurements, a total on 15 cells were taken per condition and the 
resulting traction fields were obtained. Three independent experiments were carried 
out. 
 
3.2.11 Fourier transform traction cytometry (FTTC) 
This model is based on the theory that the underlying gel is a semi-infinite solid in 
which the lateral movements (bead displacements) are small compared to the 
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thickness of the system. Once this is established any displacement 𝑑(?⃗⃗?) is 
correlated to a point of traction on the surface 𝑑′⃗⃗⃗⃗ (?⃗⃗?) using the Green’s function (𝐾) 
with the following equation187. 
 
Equation 3: 
(?⃗⃗?) = 𝐾?⃗⃗? 
In which the Green’s function K is represented by the following equation.  
 
Equation 4: 
𝐾 =  
2(1 +  𝜈)
𝐸𝑘3
 (
(1 −  𝜈)𝑘2 + 𝜈𝑘𝑦
2 −𝜈𝑘𝑥𝑘𝑦
−𝜈𝑘𝑥𝑘𝑦 (1 −  𝜈)𝑘
2 + 𝜈𝑘𝑥
2) 
 
In which 𝜈 is the Poisson ration, 𝐸 is the Young’s modulus and 𝑘 is the displacement. 
 
3.2.12 Finite element modelling cell traction force microscopy (FEM-CTFM) 
Fourier transform traction cytometry is a well-used method that is limited by the fact 
that in order to be implemented, some assumptions need to be made such as the 
homogeneity of the substrate measured as well as its isotropicity187. This allows for 
understanding the transmission of force within a relatively simple system. Studying 
a bi-layered system with a relatively soft hydrogel base coated with a thin but stiff 
layer of polymer can therefore not be carried out using this method. Finite element 
model was therefore developed in order to study this complex system. 
Bead displacement data obtained on the hydrogel surface with the MATLAB 
algorithm was also used for finite element analysis in order to determine forces 
exerted by cells on the polymer surface by modelling force transmission between 
the hydrogel-polymer interface.  
This bi-layered system was modelled, thanks to Dr. Lukasz Kaczmarczyk and Karol 
Lewandowski of the Infrastructure & Environment research division, using the Cubit 
geometry and mesh generation toolkit with the thickness and mechanical properties 
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of each polymer layer. A fine mesh factor was chosen to have higher resolution of 
displacement and traction stresses. Below is a table of parameters used for these 
models. 
 
Table 8: Mesh parameters for PEA, PMA and PSMA coated polyacrylamide 
  Polymer 
  PEA PMA PSMA 
Block 1  
(Polymer) 
Dimensions (µm)  
200 x 230 x 
0.07 
200 x 230 x 
0.1 
200 x 230 x 
0.01 
Young’s 
modulus (MPa) 
0.379 0.790 3.6.10-3 
Poisson ratio 0.49 0.49 0.48 
Mesh Factor 1 1 1 
Block 2 
(Hydrogel) 
Dimensions (µm)  200 x 230 x 50 
Young’s 
modulus (MPa) 
0.48 
Poisson ratio 3.6.10-3 
 
Traction stresses on the surface of the polymer layer were then calculated using up 
to 8 processors thanks to the university servers. Results were processed with the 
Paraview data analysis and visualisation program. Results were then compared with 
results obtained using the MATLAB algorithm. 
 
 
3.2.13 FAK and pFAK signalling 
3.2.13.1 In-cell western 
Cells were seeded into a 24-well tissue culture treated plate and left to adhere for 
2h after which culture media was removed, cells were rinsed with PBS, and, fixed 
with 4% formaldehyde.  
Seeding was done in different conditions (Figure 28). Cells were seeded using 
media with no FBS, however a positive control was used for each condition with 
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media containing 10% FBS which would in theory increase the expression of FAK. 
Furthermore, 2 seeding densities were used: 20x103 cells/cm2 and 
40x103 cells/cm2. 
 
 
Figure 28: In Cell Western experiment setup. In cell western was carried out 
in several conditions: lower or higher seeding density (2x104 and 
4x104 cells/cm2 respectively), incubated with CellTag or the antibody of 
interest (FAK/pFAK) and with or without 10% FBS. 
 
After fixing, samples were permeabilised using 0.1% Triton X-100 in PBS for 5 
minutes and rinsed 3 times with PBS before being blocked with Odyssey® blocking 
buffer (provided with the kit) for 1.5 h. Anti-FAK and anti-pFAK (Millipore, 06-543 
and 05-1140 respectively) were then added to their respective wells (1:100 each in 
Odyssey® blocking buffer) and incubated with samples for 2.5 h. Samples were 
then rinsed 5 times with 0.1% DPBS/Tween20 for 5 minutes each and then 
incubated with the secondary antibodies (IRDye® anti-mouse for FAK and IRDye® 
anti-rabbit for pFAK, 1:800 in Odyssey® blocking buffer) for 2.5 h. CellTag 700 stain 
was added to wells with cells in order to normalise values by the amount of cells. 
Only the secondary antibody was added to control wells in order to calculate the 
background. Samples were then washed in the same way as previously described 
and dried for imaging and fluorescent quantification. 
 
3.2.13.2 Western blot 
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Testing cells with PND-1186 
In order to see if PND-1186 would have an effect on their ability to adhere to the 
surface, cells were pre-treated with the drug before seeding them onto surfaces. 
DU145 cells were harvested, centrifuged and resuspended in media with no FBS 
containing 0 nM, 150 nM or 1500 nM of PND-1186. Cells were kept suspended by 
gentle agitation for 1h at 37ºC. Cells were then seeded in a 24 well plate and left to 
attach for 2h. Wells were rinsed and the nuclei of cells were stained with NucBlue 
live staining and cells were observed and images taken with the EVOS 
epifluorescent microscope in order to see if cells were able to adhere to the surface. 
 
Cell preparation and lysis 
Cells were harvested and pre-treated with PND-1186 in the same manner as the 
test. Suspended cells were incubated with 0, 150 nM or 1500 nM of PND-1186 
under agitation at 37ºC for 1h and then seeded onto 32 mm ø round coverslips 
coated with PEA, PMA, or bare glass at 2x104 cells/cm2 (in 6-well plates) for 2h at 
37ºC. Wells were then rinsed with TBS and cells were lysed on ice and scraped with 
RIPA buffer containing protease and phosphatase inhibitors. Lysates were collected 
in protein low binding Eppendorf tubes and stored at -80ºC until ready to use to 
prevent protein degradation.  
 
Cell lysate protein concentration 
Protein concentration of the cell lysate was determined using micro BCA 
(bicinchoninic acid) assay. Due to the fact that this assay has a detection threshold 
between 2-40 µg/ml, the lysate was diluted 1:10 and 1:60. 
 
Protein concentration 
Cell lysate was thawed on ice and 100 µg of protein for each lysate was placed into 
Microcon® 30 K protein columns. Tubes were then centrifuged at 1.8x104 rcf for 10 
minutes at 4ºC to remove lysis buffer. 25 µl of RIPA buffer was then added to 
resuspend the protein and the sample was placed in a collection tube to collect the 
concentration protein and centrifuged at 13x103 rpm for 1 minute at 4ºC. This was 
done in order to be able to successfully load 10 µg of protein in each gel. 
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Gel electrophoresis and transfer 
Loading buffer (4x Laemmli with 20% β-mercaptoethanol) was added to the 
concentrated lysate. The sample was then heated at 95ºC for 5 minutes to further 
denature the protein and then put on ice. The sample was then loaded into a TGX 
7.5% precast gel (BioRad 4561024). The gel was run at 70 V for about 2h and then 
transferred onto a nitrocellulose Western blot membrane for 45 minutes at 25 V. 
 
Antibody incubation 
The membrane was then cut in several pieces for the different antibodies and 
blocked with TBS with 5% BSA for 30 minutes at RT. Membrane pieces were then 
incubated with anti-FAK, anti-pFAK and α-Tubulin in TBS with 5% BSA overnight at 
4ºC. 
Samples were then washed 3 short times followed by 3 washes of 5 minutes each 
with TBS/Tween20 0.1%. Membranes were then incubated with their respective 
secondary antibodies (1h at RT with 5% BSA in TBS) and then washed in the same 
manner as the previous step.  
Membranes were then dried and ECL was put onto membranes for 5 minutes in the 
dark. Excess ECL was then removed and placed onto a digital reader in order to 
visualise the blots. 
 
3.2.13.3 FAK/pFAK staining and fluorescent quantification 
Cell culture and fixing 
DU145 cells were harvested by trypsinisation and incubated in suspension with 
agitation for 1h with 0 nM, 150 nM or 1500 nM of PND-1186 at 37°C, 5% CO2. Cells 
were then seeded onto PEA, PMA and glass coverslips coated with 20 µg/ml of FN 
for 3 hours. Media was removed and cells were rinsed with warm PBS before fixing 
with paraformaldehyde 4% for 20 min at 4°C. 
 
Cell staining and imaging 
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Coverslips were then permeabilised with 0.5% triton-100X for 5 min and then 
blocked with 1% BSA for 30 min. Samples were then incubated with anti-FAK 
produced in rabbit (Millipore, Ref. 06-543) at 1:100 dilution and anti-pFAK produced 
in mouse (Millipore, Ref. 05-1140) at 1:200 dilution for 1h at RT. Samples were then 
rinsed twice with 0.5% Tween20 and incubated with goat anti-rabbit Cy3 (Jackson 
Immuno Research, Ref. 111-165-003, 1:200 dilution), donkey anti-mouse Alexa 488 
(Life technologies, Ref. A21202, 1:2000 dilution) and Alexa 660 Phalloidin (Life 
Technologies, Ref. A22285, 1:200 dilution) secondary antibodies for 1h at RT, 
protected from light. Samples were then rinsed twice and mounted using 
Vectashield® with DAPI. Fluorescent images of samples were taken for 20 cells per 
condition using the ZEISS Z1 inverted auto fluorescent microscope. 
 
Fluorescent intensity measurements 
Total fluorescent intensity was measured with ImageJ using a method described by 
McCloy, R. A. et al.189. For each image, the contour of the cell was selected and the 
area, integrated density (product of the area and mean grey value), and mean grey 
value were measured using the analyse menu. The fluorescent intensity of the 
background was also measured by averaging at least 3 different areas outside of 
the cell. From this the corrected total cell fluorescence (CTCF) was calculated using 
the following formula: 
CTCF = Integrated Density – (Area of selected cell x Mean fluorescence of 
background readings).  
 
 
 
pFAK image analysis and quantification (FAAS) 
The number, area and size of pFAK aggregates observed were measured using the 
FA analysis server. This was done due to the fact that although they are not the 
same, pFAK aggregates had a similar layout to FAs. 
 
3.2.14 Statistical analysis 
Two-way ANOVA was used for the comparison of the different groups using a 
Bonferroni post-test to compare all columns. Data is represented as mean ± SD and 
the differences between groups were considered significant for P<0.05. 
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3.3 Results 
3.3.1 DU145 growth and cytotoxicity 
The proliferation of DU145 human prostate cancer cells was measured using MTT 
and alamarBlue® assays.Growth by measuring absorbance using the MTT assay 
and fluorescence using alamarBlue® showed similar evolutions for both seeding 
densities. For the MTT assay, a sigmoidal shaped curve is observed for the lower 
seeding density of 1500 cells/cm2 (Figure 29 A) whereas cells seeded at 
15000 cells/cm2 grew quicker at the beginning before stabilising after 3 to 4 days. 
For the growth using alamarBlue®, cells grow quickly for the first 3 days but grow 
more slowly up to the 7th day (Figure 29 B). 
Growth on polymers with and without FN was observed using alamarBlue®. For the 
lower seeding density (Figure 29 C), cells do not proliferate on PEA and PMA 
without FN. If FN is added cells start growing after 4 days and appear to grow much 
faster on PMA than on PEA. 
For the higher seeding density (Figure 29 D), cells seem to grow on PEA and PMA 
with and without FN. However, there are initially less cells on non-coated surfaces. 
This can be due to the fact that although the same number of cells were initially 
seeded, because there is no pre-existing FN some cells detach more easily. Cells 
grow immediately but at a slower pace than or the lower seeding density possible 
because of the number of cells and confluence inhibiting growth.   
 
 75 
 
 
Figure 29: DU145 human prostate cancer growth over 7 days with MTT and 
alamarBlue® assays. (A) MTT assay on 96-well plate. (B) Alamar blue on 24-
well TCP. (C) and (D) AlamarBlue® on PEA and PMA with (straight lines) 
and without (dotted lines) FN. Error bars for (C) and (D) are hidden in the plot 
symbols. A total of 3 independent experiments were carried out with 
triplicates per condition. 
 
Cytotoxic studies were carried out using docetaxel (DOC), a potent 
chemotherapeutic cytotoxic drug used to bind microtubules and leading to cell death 
and PND-1186, a cytostatic drug that inhibits FAK currently in phase I of clinical 
trials (Figure 30). 
Cell viability with DOC followed a standard sigmoidal pattern with a maximum 
percentage of cells alive (100% viability) for lower concentrations of drug and all 
cells dead (0% viability) for the highest concentrations of drug. The IC50, which is 
the concentration at which there is 50% cell viability was determined for cells on 
TCP, as well as FN-coated PEA, PMA and glass coverslips. The IC50 of cells on 
TCP and FN-coated glass were 6.9 nM and 8.06 nM respectively (Figure 30 A), 
comparable with values described by the Wellcome trust Sanger Institute’s 
genomics of drug sensitivity in cancer project.190 Cells on PEA and PMA however 
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presented higher IC50 values of 28.6 nM and 20.21 nM respectively, indicating 
polymer-related resistance independent of FN conformation. 
 
Table 9: Cell viability with docetaxel and PND-1186 on PEA, PMA, glass and 
TCP. 
Drug Docetaxel PND-1186 
Surface PEA PMA GLASS TCP TCP 
Max 85% 97% 100% 100% 95% 
Min 11% 10% 10% 0% 40% 
IC50 28.6 nM 20.21 nM 8.06 nM 6.9 nM N/A 
 
Cell viability with PND-1186 showed no sigmoidal pattern (Figure 30 B) with 
maximum viability at up to 1 µM and a minimum viability at approximately 40% with 
0.5 nM. It has been previously reported that PND-1186 has a cellular IC50 of 100-
150 nM, determined by anti-phospho-specific immunoblotting to FAK Tyr-397101, 102 
and resulted in restricted movement. Cell apoptosis using this drug has only been 
reported in non-adherent conditions. 
 
 
Figure 30: DU145 cytotoxicity assays with (A) Docetaxel (DOC) and (B) PND-
1186 (PND). Docetaxel studies were carried out on TCP as well as PEA, 
PMA and glass coverslips coated with 20 µg/ml of FN. PND-1186 studies 
were carried out solely on tissue culture plastic. 
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3.3.2 Cell attachment and focal adhesion formation 
Short term cell attachment assays were carried out with DU145 cells on PEA, PMA 
and glass coverslips coated with FN. This was done in standard conditions and after 
blocking the RGD domain and PHSRN synergy sequence with HFN7.1 and 
mAb1937 antibodies respectively.  
Polymers coated with FN showed 100% attachment even after washes (Figure 31). 
When the RGD cell binding domain was blocked with HFN7.1 (H) 7-8% percent of 
cells remain attached. When the PHSRN synergy sequence was blocked with 
mAb1937 (m) there was partial inhibition of cell attachment on PEA with no effect 
on attachment on PMA, highlighting the difference in domain availability of PHSRN 
on FN adsorbed to PEA and PMA. When both domains were blocked together less 
than 10% of cells remained attached on both surfaces. 
 
 
Figure 31: 20-minute attachment assay of DU145 cells on FN-coated PEA 
and PMA, blocked with HFN7.1 and/or mAb1937 antibodies. DU145 cells 
were seeded onto PEA and PMA coated with 20 µg/ml of FN after blocking 
the RGD and PHSRN sequences using HFN7.1 (H) and mAb1937 (m) 
respectively at a 1:1 FN:antibody molar ratio. N = 3; n = 3, ***p<0.001. 
 
Early adhesion assays of 3 hours were carried out on PEA and PMA with 2, 5, 10 
and 20 µg/ml of FN in standard conditions and blocking RGD and/or PHSRN 
sequences. Cell size and FAs were quantified for all conditions. 
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Cells were of similar size on both polymers for lower concentrations of FN 
(~1000 µm2), however, for 20 µg/ml of FN cells were more spread on PEA 
compared to PMA with sizes of roughly 1800 µm2 and 1500 µm2 respectively (Figure 
32 A). Although FAs were the same size in all conditions (Figure 32 C), there were 
more of them on PEA than on PMA with 2 and 20 µg/ml of FN (Figure 32 B). This 
resulted in significantly higher moment of inertia on PEA with those concentrations 
of FN. 
 
 
Figure 32: Cell spread and FA analysis of cell on PEA and PMA coated with 
2, 5, 10 and 20 µg/ml of FN (denoted FN2, FN5, FN 10 and FN20 
respectively) for 3 hours. (A) Cell size. (B) FA count. (C) FA size. (D) Moment 
of Inertia. n = 30, *p<0.05, **p<0.01, ***p<0.001. 
 
A detailed analysis of FA size distributions (Figure 33) on polymers with different 
concentrations of FN revealed that although there was a higher proportion of small 
FAs  of 1 µm on PMA, no differences in overall size was observed.  
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Figure 33: FA size distribution on PEA and PMA coated with 2, 5, 10 and 20 
µg/ml of FN (denoted FN2, FN5, FN 10 and FN20 respectively). Size 
distribution of FAs were assessed on FAs equal to or larger than 1 µm in 
length and were binned at every 0.2 µm interval up until 3 µm. N=10. 
 
The RGD cell binding domain and PHSRN synergy sequences were blocked on 
samples coated with 20 µg/ml of FN (Figure 34). In standard conditions with no 
blocking, cells were well spread on all surfaces with actin stress fibres and vinculin 
well defined. 
 80 
 
 
Figure 34: Representative images of DU145 cells on PEA, PMA and glass 
coated with 20 µg/ml of FN after 3-hour early adhesion with HFN7.1 (H) 
and/or mAb1937 (m) antibodies. Composite images (above) and their 
respective vinculin images (below) are shown. Cells on surfaces that weren’t 
blocked were well spread with prominent FAs. Blocking the RGD domain 
and/or the PHSRN synergy sequence with HFN7.1 and mAb1937 
respectively led to cells with poorly defined cytoskeleton structures and lack 
of FA formation. This is with the exception of cells on the fibrillar FN on PEA 
where cells were spread with well-defined FAs even when the synergy 
sequence is blocked. Scale bar: 50 µm 
 81 
 
 
When the RGD cell binding domain was blocked with HFN7.1, no FAs formed and 
although the cells were spread the actin cytoskeleton appeared very disorganised 
with no visible stress fibres. When the PHSRN synergy sequence was blocked with 
mAb1937, cells on PEA behaved normally with cells spread out and a normal FA 
distribution. This is opposed to cells on PMA and glass where there were no FAs 
and cells were rounded. When both sequences were blocked cells were spread out 
on all surfaces with no FAs.  
The difference observed when blocking the synergy sequence is in some way linked 
to the differences in conformation of FN and availability of this sequence on PEA 
and PMA. Due to the fact that the PHSRN sequence of FN is less exposed on FN-
coated PMA compared to PEA (Figure 19 B) we can hypothesise that when this 
sequence is blocked using mAb1937, the antibody can more easily block the fewer 
synergy sites presented on PMA as opposed to the higher amount of available 
PHSRN sequences present on FN-coated PEA.  
 
3.3.3 Cell migration 
Cells were seeded onto polymers coated with 20 µg/ml FN and incubated with PND-
1186, a cytostatic drug, at different concentrations: the cellular IC50 (~150 nM) and 
an excessive amount (1500 nM). Cells were then imaged and gap closure was 
measured (Figure 35, Figure 36). 
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Figure 35: Wound healing assay time-lapse representative images at 0, 8, 16 
and 24 hours with 150 nM and without PND-1186. In normal conditions 
without PND-1186, cells were able to close the 500 µm gap within 16-24 
hours. Adding the drug at a concentration close to its cellular IC50 led to cells 
migrating slower, not closing the gap in many cases after 24 hours. Scale 
bar: 500 µm. 
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Figure 36: Wound healing assay gap closure analysis of cells on PEA, PMA 
and glass in standard conditions and with 150 and 1500 nM of PND-1186 
over the course of 18 hours. (A) Comparison of polymers per concentration. 
(B) Comparison of concentrations per polymer. The area of the gaps was 
measured to determine gap closure. n = 12. 
 
In standard conditions with no drug, cells close the 500 µm gap within 15 hours on 
PEA whereas only 80% of the gap was closed on PMA surfaces after 18 hours. 
Cells could close the gap on glass after 18 hours. A noticeable decrease in cell 
migration was observed when incubated with PND-1186, notably on PEA and glass 
whereas the effect was minimal on PMA. Cells migrate faster on PEA compared to 
other surfaces in normal conditions as well as in the presence of a cytostatic drug, 
highlighting the importance of FN conformation and domain availability in cell 
migration. This allows to infer that fibrillary FN, as it is found in the ECM enhances 
cell migration. 
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3.3.4 Cell traction force microscopy – finite element analysis 
3.3.4.1 Traditional CTFM 
A total of 3 independent experiments were carried out, looking at 15-20 cells per 
condition for each experiment. The following results are the combined results of 
these experiments (Figure 37). 
 
Figure 37: Representative images of CTFM analysis on different surfaces. 
(A) DU145 cells on PAA, PSMA, PEA and PMA with an outline delimiting the 
cell contour. (B) Displacement field: highlighting the movement of the 
microbeads. (C) Traction field: obtained by equating the displacement of the 
beads to the stress exerted by cells on the substrates. Displacement and 
traction field scales are arbitrary from low displacement/traction (dark blue) 
to high displacement/traction (dark red). Scale bar: 50 µm.  
 
In the case of the displacement and tractions fields, it is important to note that colour 
intensity scales are different for each cell. What is also immediately noticeable is the 
fact that cells on PAA alone are rounded indicating that FN does not adsorb to PAA 
alone therefore preventing cells from adhering properly. 
The CTFM results are from 3 independent experiments analysing a total of 30-45 
cells per condition (Figure 38). Large error bars are due to high variability between 
cells. 
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Figure 38: Characterisation of PAA hydrogels coated with PSMA, PEA and 
PMA polymers and CTFM analysis using MATLAB script of DU145 cells 
seeded onto PAA alone or PAA coated with PSMA, PEA or PMA for 3 h. (A) 
Force spectroscopy measurements of PAA alone, and PAA coated with 
PSMA, PEA or PMA. (B) DU145 cell size after 3 hours adhesion on each 
substrate coated with 20 µg/ml FN. (C) Strain energy which is the energy 
stored in the gels undergoing deformation. (D) Maximum and (E) total traction 
stress which is the stress on the surface exerted by the cell. (F) Total force 
(product of stress and surface area). Traction stresses were directly 
proportional to the stiffness values measured by force spectroscopy, bringing 
into question the methods used to assess stiffness of the hydrogel-polymer 
system. N = 3; n = 15, ***p<0.001. 
 
In order to determine the forces cells were exerting on each system, the stiffness of 
substrates was measured by force spectroscopy. PAA substrates had a stiffness of 
3.5 kPa which was similar to PSMA coated PAA (4 kPa). This confirms that PSMA 
coating has no significant effect on the stiffness of the hydrogel, most likely due to 
the fact that the PSMA coating is very thin (10-20 nm). Upon measuring PEA and 
PMA coated hydrogels, a 6 to 7-fold increase in stiffness is observed (22 and 25 kPa 
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respectively). Just as with PSMA, this is in large part due to the polymer thickness 
(100 nm for PEA and 70 nm for PMA). This difference in stiffness is then taken into 
account in measuring the mechanical properties of the system such as strain 
energy, traction stress and force.  
Cell size on polymer coated PAA is similar (around 1000 µm²) whereas cells are 
significantly smaller on PAA alone (around 400 µm²) indicating that cells do not 
attach or spread very well on the bare hydrogel.  
Strain energy is inexistent on PAA but is similar on polymer coated PAA with an 
increase in strain energy from PSMA to PMA. This value varies most between cells 
which causes high error bars.  
Values of the maximum traction stress, total stress and total force are similar 
between PAA and PSMA whereas a significant increase for these values is 
observed for PEA and PMA. These results directly reflect the differences in surface 
stiffness.  
 
3.3.4.2 Finite element modelling CTFM 
FEM-CTFM was done in order to have a more correct depiction of force 
transmission within the polymer-hydrogel bi-layered system.  
A total of 10 cells per condition (PSMA, PEA and PMA) were used as 
representatives in order to compare results obtained through standard CTFM and 
finite element analysis. Maximum stress and total force were calculated (Figure 39). 
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Figure 39: Maximum stress (top) and total force (bottom) of cells on PSMA, 
PEA, and, PMA determined by standard CTFM and finite element modelling. 
n = 10, *p<0.05, ***p<0.001. 
 
Cells on PSMA-coated polyacrylamide exerted very little stress on the surface. Both 
analysis methods have similar values with a maximum stress of 90 – 100 Pa and 
total force of 175 – 185 nN. The layer of PSMA was very thin (~10-20 nm) and 
therefore is considered negligible. Furthermore, the stiffness (~4 kPa) was very 
close to bare PAA (~3.5 kPa) while still allowing FN and therefore cell binding.  
The maximum stress of cells on PEA-coated PAA was measured to be ~300 Pa with 
standard CTFM using a MATLAB script compared to ~175 Pa obtained by finite 
element modelling. Discrepancies between CTFM and FEM were also observed in 
total force with ~535 nN and ~210 nN respectively. 
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Similarly to cells on PEA, differences were observed between CTFM and FEM 
methods for PMA, with high variability using the latter. The maximum stress was 
recorded at ~280 Pa by CTFM and ~790 Pa by FEM whereas the total force was 
recorded at ~580 nN by CTFM and ~1350 nN by FEM. 
The differences between both methods are especially pronounced in cells on PEA 
and PMA coated polyacrylamide. 
 
3.3.5 Expression of FAK and pFAK 
3.3.5.1 In-cell western 
The following Figure 40 and Figure 41 show the results of the in-cell western. 
 
 
Figure 40: Merged image of fluorescent scanning of plate stained with 
FAK/pFAK antibodies (green) and CellTag 700 (red). FAK was detected at 
high (40k - 40.103 cells/ml) and low (20k - 20.103 cell/ml seeding densities 
with the appearance of a ring of cells at the edges due to pipetting errors. 
pFAK was not detected in this instance highlighting the inefficacy of this 
method (or the antibody) for detecting pFAK expression. Scale bar: 15 mm. 
 
The wells stained with anti-FAK have a high fluorescent signal whereas wells 
stained with anti-pFAK have very little green signal compared to the CellTag total 
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cell staining. The traces of pFAK staining are similar to the background noise 
observed in the negative control which indicates that the pFAK antibody was not 
effective in staining. This in reinforced by the fact that in the positive control wells 
with 10% FBS where it is expected to have a higher expression of FAK/pFAK there 
is no sign of pFAK staining. 
It is also worth noting that there is a ‘coffee ring’ effect on the edges of the wells 
where a lot of cells are aggregated. This is due to the way in which cells were seeded 
in the wells by pipetting quickly in the centre of the well resulting in most cells going 
to the edges.  
 
The fluorescent intensities of this image were also analysed. Values were obtained 
by subtracting the background noise of each condition from the values.  
 
 
Figure 41: Fluorescent intensities of FAK and pFAK in DU145 cells (800) 
normalised by total cell amount (CellTag 700) after seeding 2.104 (20k) and 
4.104 (40k) cells/cm2 with and without 10% FBS for 2 h. FAK is detectable in 
all conditions whereas pFAK in not detected even in the optimal conditions 
(high seeding density of 4.104 cells/cm2 with 10% FBS) highlighting the 
inefficacy of this method and/or the questionable quality of the pFAK 
antibody. 
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These results show that FAK can be detected using this system with both seeding 
densities. Interestingly, there appears to be a decrease in FAK expression when 
cells are seeded with 10% FBS. Furthermore, pFAK does not seem to be detected 
in any conditions, as the little amount of fluorescence is most likely due to 
background noise by unspecific binding of the secondary antibody.  
The in-cell western method does not appear to be sensitive enough to detect the 
small quantities of pFAK expressed by the cells. Ultimately, this method is not 
effective for detecting the phosphorylation of FAK in cells due to the lack of 
sensitivity of the system or the quality of the antibody used.  
 
3.3.5.2 Western blot 
Western blot was also used in order to quantify FAK/pFAK expression in DU145 
cells that were incubated with 150 nM and 1500 nM of PND-1186. Cells were first 
harvested, and the protein concentration was measured by micro BCA in order to 
load the same amount of protein in each well (Figure 42). 
 
 
Figure 42: Lysate protein concentration of cells seeded onto PEA, PMA and 
glass coated with 20 µg/ml of FN after PND-1186 treatment. 
 
The protein concentration of cell lysates for each condition was measured. 
Concentrations were between 0.8-1.7 mg/ml, which was enough to load gels without 
the need to use protein columns for concentration. These lysates allow loading of 
10 µg of protein in wells using a small volume (5-10 µl of lysate). 
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Figure 43: Expression of pFAK, FAK and α-Tubulin in DU145 on PEA, PMA 
and glass after treatment with PND-1186. pFAK and FAK bands are very 
weak with the appearance of double bands in the case of pFAK whereas α-
tubulin bands are clear but don’t show consistent amounts of protein. These 
results can therefore not be used to assess FAK/pFAK expression. 
 
 
Bands were visible for each protein (pFAK, FAK, α-Tubulin). Although they are very 
clear for α-tubulin, there appears to be more background for FAK and pFAK. In the 
case of pFAK there appears to be double bands which was not due to protein 
degradation seeing as tubulin bands are intact.  
 
Several attempts were made to quantify FAK/pFAK expression using this technique 
but to no avail. Cells were therefore stained in order to quantify fluorescent intensity. 
 
3.3.5.3 Immunofluorescent quantification 
The following images (Figure 44) represent cells on PEA, PMA and glass coated 
with FN after incubation with PND-1186. 
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Figure 44: FAK and pFAK staining of DU145 cells on FN coated PEA, PMA 
and glass after a 1h incubation with 0 nM, 150 nM and 1500 nM PND-1189. 
pFAK appears to be at the edge of the cell where FAs are expected to be 
whereas FAK staining only appears within the cytoplasm with no distinct 
organisation. This might indicate that the FAK antibody has not been 
effective. Scale bar: 50 µm. 
 
With no drug, cells appear to be well spread on all surfaces with pFAK organised in 
a similar fashion to FAs. Interestingly, there appears to be no co-localisation 
between FAK and pFAK (Figure 44) suggesting that the FAK antibody might not 
have been effective. 
With increasing amounts of PND-1186, cells on PEA and PMA appear smaller with 
less organised pFAK especially in the case of cells on PMA. A similar effect can be 
observed on glass although the size appears to be more consistent.  
The organised pFAK was measured (using only 5 cells per condition) along with the 
cell size (20 cells per condition). 
It has already been established that in normal conditions with no drugs, cells are 
larger on PEA compared to PMA and the same is observed in this instance. 
Furthermore, cell size decreases significantly in the presence of PND-1186 on both 
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polymers (Figure 45 A). This is observed with cells on PEA and PMA between 0 nM 
and 150 nM and 150 nM and 1500 nM of PND-1186 respectively. A similar trend is 
observed with cells on glass. 
Moreover, the amount of organised pFAK is higher in cells on PEA compared to 
PMA in normal conditions (Figure 45 B). This reinforces previous results which 
showed that there are more FAs in cells on PEA compared to PMA. In the presence 
of PND-1186, the amount of pFAK decreases significantly on PEA as opposed to 
PMA where the amount of pFAK remains consistently low. At the highest 
concentration of drug, no pFAK aggregates were measured on PMA. Although not 
significant, a similar trend of decrease in pFAK was observed in cells on glass. 
 
 
Figure 45: (A) Cell size and (B) organised pFAK count of cells on PEA, PMA 
and glass with 0 nM, 150 nM and 1500 nM of PND-1186. pFAK count was 
determined using the FAAS. N = 20 for cell size, N = 5 for organised pFAK 
count. * P < 0.1, ** P < 0.01, *** P < 0.001. 
 
The size and area of organised pFAK was measured with the same tool used for FA 
analysis in order to see if there were any relation between the concentration of PND-
1886 and the expression and organisation pFAK in cells on PEA and PMA (Figure 
46). 
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Figure 46: Size and area distribution of pFAK. (A)(B) Comparing PEA, PMA 
and glass (size and area respectively). (C)(D) Comparing PND-1186 
concentration (size and area respectively). N = 5. 
 
PEA has larger organised pFAK aggregates compared to PMA with no drug, 
however this does not appear to be the case with 150 nM of drug. With 1500 nM of 
PND-1186, organised pFAK is not present. 
 
Fluorescent intensity of FAK and pFAK was also quantified using ImageJ. The 
following Figure 47 represents corrected total cell fluorescence of FAK and pFAK. 
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Figure 47: Corrected total cell fluorescence of cells on PEA, PMA and glass 
with 0 nM, 150 nM and 1500 nM of PND-1186. (A) pFAK fluorescent 
intensity. (B) Total FAK fluorescent intensity. (C)(D) Ratio of pFAK to total 
FAK. Total cell fluorescence only took into account FA-like structures. n = 20. 
** P < 0.01, *** P < 0.001. 
 
In cells on both PEA and PMA, there is a significant decrease in pFAK fluorescent 
intensity with increasing concentrations of PND-1186. There are no significant 
differences between polymers. In the case of total FAK, there is a decrease in cells 
on PEA between 0 nM and 1500 nM of drug. Although a similar trend is observed in 
cells on PMA, it is not significant. In comparing the ratio of pFAK to total FAK no 
noticeable differences were observed. The proportion of pFAK to total FAK 
remained constant at 7-10% in all conditions. 
 
Fluorescent intensity measurements do no reveal differences between PEA and 
PMA in terms of the amount of pFAK compared to total FAK. However, pFAK is 
organised much differently on PEA with more structures resembling FAs, even with 
higher concentrations of drug compared to PMA. 
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3.4 Discussion 
3.4.1 FN conformation and cell behaviour 
Material-induced FN conformation has previously been shown to affect cell 
behaviour such as cell size and FA assembly in L929 fibroblasts5. Similar effects 
are seen in DU145 with cells being more spread and having a larger FA count on 
PEA leading to higher moment of inertia value (Figure 32). 
Upon blocking the FNIII9 and FNIII10 domains of FN with mAb1937 and HFN7.1 
monoclonal antibodies, clear differences could be seen in short term cell attachment 
(Figure 31) and FA formation (Figure 34). The RGD cell binding domain is essential 
for cell binding and the formation of FAs whereas blocking the PHSRN synergy 
sequence with mAb1937 did not drastically affect cell attachment. With mAb1937 
blocking alone, ~100% of cells on FN-coated PMA remained attached after rinsing 
with PBS compared to ~60% of cells on PEA. As previously demonstrated in chapter 
2, the fibrillar conformation of FN allows for more exposure of the PHSRN synergy 
sequence on PEA compared to PMA. However, cells adhere equally to both 
surfaces when coated with FN. It is therefore feasible that, depending on the 
conformation of FN, DU145 cells adhere using different integrins for binding to FN. 
Knowing that α5β1 and αvβ3 integrins are required to bind to RGD whereas only αvβ3 
is required to bind PHSRN50, 158, cells on PMA attach to FN preferentially via RGD 
sequence via αvβ3 therefore blocking mAb1937 has no effect on attachment. Cells 
on PEA however, attach via α5β1 which requires both the RGD cell binding domain 
and the PHSRN synergy sequence. This theory is confirmed by the partial decrease 
in cell binding once the synergy sequence is blocked with mAb1937.  
Furthermore, upon blocking RGD alone or in conjunction with PHSRN cells 
appeared to be more rounded with no visible FA formation (Figure 34). 
Nevertheless, when the synergy sequence alone is blocked, cells on PEA are able 
to spread and form FAs as opposed to cells on PMA and glass. Because FN has an 
extended fibrillar conformation on PEA, more domains for cell binding and FAs are 
available allowing cells to attach even when the synergy sequence is blocked5.  
Similar results were also seen with L929 fibroblasts (Figure 23 A) with cells not being 
able to attach when the RGD domain was blocked however, when the synergy 
sequence is blocked, fibroblasts attach partially to PEA and not fully as seen with 
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prostate cancer cells (Figure 31). Moreover, the same effect on cell attachment isn’t 
observed when both domains are blocked with cancer cells not being able to attach 
whereas fibroblasts were able to partially attach to PEA. It is known that cell 
phenotype has an effect on integrin expression57 with cancerous cells selectively 
secreting specific integrins involved in cell binding53. These discrepancies are most 
likely due to the expression of integrins in these two cell types with one cell type 
being healthy mouse fibroblast and the other being human metastatic epithelial 
cells.  
At first glance, these findings using DU145 human prostate cancer cells appear to 
contradict Livant et al. who reported that the synergy sequence alone was needed 
for DU145 invasion49. However, in the aforementioned study cell motility was 
investigated whereas studies performed in this instance are for static cell properties 
such as attachment and adhesion. Many studies have looked into the effect of the 
PHSRN sequence on cell motility191 as well as the effect of RGD on cell anchorage 
and inhibiting migration192, 193. A study carried out by Overstreet et al. showed that 
cell motility was impaired in WT15 T cells when β1 was blocked, therefore blocking 
activity of α5β1 which binds to both RGD and PHSRN sequences. Blocking β3 which 
inactivates αvβ3 that binds RGD alone did not show as much of an effect on 
motility191.  
The hypothesis therefore suggesting being that the RGD domain is necessary for 
cell stability and anchorage whereas the PHSRN synergy sequence in vital for cell 
motility such as migration and invasion.  
 
3.4.2 Cytotoxic studies and material-induced drug resistance 
On glass and tissue culture plastic, DOC had an IC50 of 8.06 nM and 6.9 nM (Figure 
30A) which were within the same order of magnitude of what has been previously 
reported for DU145 cells190. The IC50 of cells on PEA and PMA coated with FN was 
higher, at 28.6 nM and 20.21 nM respectively implying a form of material-induced 
drug resistance. This could possibly be due to the physico-chemical nature of the 
polymers. As with most drugs, docetaxel is partially insoluble in aqueous solutions 
and needs to first be dissolved in an organic solvent such as DMSO. The 
hydrophobic drug could potentially interact preferentially with the hydrophobic 
polymers instead of remaining in solution, therefore limiting its effectiveness. 
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PND-1186 is powerful FAK inhibitor with a cellular IC50 of ~100 nM. This was 
determined in breast carcinoma cells by anti-phospho-specific immunoblotting in a 
study by Tanjoni et al.101. Cytotoxicity studies were carried out here on tissue culture 
plastic with no apparent effect on cell viability at up to 10 times the reported IC50. 
Moreover, although FAK is inhibited, this did not affect cellular adhesion which has 
also been previously reported by Tanjoni et al.  
PND-1186 could therefore be considered as a cytostatic drug inhibiting migration 
and tumour progression and not cytotoxic102.  
 
3.4.3 Migration and traction forces 
3.4.3.1 Cell migration 
Wound healing assay (or scratch test) is a standard experiment used to assess cell 
motility194-196. It is a particularly useful screening method for the development of 
therapies and treatment of highly mobile cancerous cells. Without drugs, DU145 
cells migrate significantly faster on PEA than on PMA (Figure 36), closing the gap 
within 15 hours whereas the 500 µm gap remains open after 18 hours on PMA. Both 
surfaces are sensed as “stiff” by the cell with Young’s moduli of ~400 kPa and 
~800 kPa on PEA and PMA respectively (Table 8) which are well over 
physiologically ‘soft’ tissue (1 – 20 kPa)12. The difference in motility appears to be 
entirely due to the conformation of FN on the surface. FAs were shown to have 
comparable sizes with a larger number of FAs on PEA compared to PMA (Figure 
32B and C). The increased availability of integrin binding sites of stretched out FN 
leads to the formation of more FAs. Although these serve as anchorage points for 
the cell they are equally as important in cell motility, notably in cancer cell migration 
and invasion197-199. This suggests that a larger number of FAs on PEA are due to 
higher activity (formation and disassociation of FAs) and therefore more mobile 
cells. Therefore FAs aid cell migration in the case of high turnover of FA association 
and disassociation and slow down migration with low turnover thus anchoring the 
cell. 
FAK  plays a commanding role in cell motility62. Therapeutic agents aimed at 
inhibiting this enzyme are therefore becoming more and more popular104, 200, 201. 
PND-1186 has previously been shown to reduce the motility of 4T1 breast cancer 
cells with 60% of inhibition at 400 nM while unaffecting cell binding to FN101. With 
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increasing amounts of PND-1186 (150 nM and 1500 nM) a decrease in cell motility 
was observed on PEA with cells not managing to close the gap after 18 hours with 
1500 nM of drug. This effect was not seen in cells on PMA where the gap closure 
was unchanged. This can be explained due to the lack of pFAK organisation in cells 
on PMA (Figure 44) making it less sensitive to the effects of a FAK-inhibiting drug.  
 
3.4.3.2 Traction forces 
Traction forces were initially measured using standard CTFM. These results 
indicated that the stiffness used for the model play a determining role in the results 
obtained. Stress and force values proportionally reflect the stiffness measured by 
force spectroscopy. However, this raises the question as to the aptness of using 
force spectroscopy to measure the stiffness of the bi-layered system.  
Polymer layers are sufficiently thin to allow the transfer of forces from the surface to 
the underlying hydrogel as seen by the bead displacement located in the PAA 
(Figure 37). However, it remains unclear if the stiffness measured on the surface of 
the polymer coated hydrogels are the correct values to use.  
AFM nanoindentation was used to determine the stiffness of the polymer-hydrogel 
system. This method is a highly sensitive technique which consists of indenting the 
surface of the measured substrate with a cantilever (in this case with a tip consisting 
of a spherical bead between 5 – 20 µm in diameter) (Figure 48). A small area of 
interaction between the bead and the surface allows for it to be highly sensitive. 
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Figure 48: Young’s modulus of polyacrylamide alone and PSMA, PEA and 
PMA coated PAA along with nanoindentation parameters used. 
 
The indentation depth x along with the spring constant k are used to determine 
indentation force F using Hooke’s law: 
Equation 5: Hooke’s law used to determine nanoindentation force. 
𝐹 = 𝑘𝑥 
Along with the indentation depth and force F, the radius of the sphere as well as the 
radius of contact are used in the Hertz model in order to deduce the Young’s 
modulus E. 
Equation 6: Hertz model used to deduce the Young’s Modulus E 
F =
𝐸
1 − 𝜈2
 [
𝑎2+ 𝑅𝑠
2
2
𝑙𝑛
𝑅𝑠+𝑎
𝑅𝑠 −𝑎
 − 𝑎𝑅𝑠]   ⇔    𝐸 =  
𝐹(1−𝜈2)
[
𝑎2+ 𝑅𝑠
2
2
𝑙𝑛
𝑅𝑠+𝑎
𝑅𝑠 −𝑎
 −𝑎𝑅𝑠]
 
F: Indentation force 
𝞄: Poisson’s ratio 
a: Radius of the contact circle 
Rs: Radius of sphere 
E: Young’s modulus 
 
This model assumes that the system measured is isotropic (having identical values 
of a property in all directions) meaning that vertical forces deduced by 
nanoindentation can be applied to lateral displacements (i.e. lateral cell forces and 
bead displacement within the PAA hydrogel). However, this method fails to take into 
account a bi-layered system in which, in the case of PEA and PMA coatings, a 
relatively stiff layer of polymer (400 – 800 kPa) with considerable thickness (70 – 
100 nm) is covering a much softer layer of PAA hydrogel (3 – 4 kPa). A bi-layered 
system using different substrates with completely different mechanical properties 
poses a much more difficult problem when trying to measure traction forces of cells.  
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Finite element modelling was therefore used to determine forces exerted by cells on 
the polymer surface by modelling force transmission between the hydrogel-polymer 
interface. These results were then compared with values obtained using standard 
CTFM (Figure 49).  
 
Figure 49: Finite element modelling traction field compared to standard 
traction field. Standard Fourier transform traction cytometry (top) uses the 
displacement of beads (or nanopillars) to obtain a displacement field which 
is converted to a traction field by knowing the mechanical properties of the 
system and applying the Green’s function. This is especially useful when the 
substrate used is homogeneous. In the case of a heterogeneous bi-layered 
system, finite element modelling is used (bottom). This involves measuring 
the mechanical properties (Young’s modulus E and Poisson's ratio v) of each 
layer, incorporating the previously obtained displacement field within a 
triangular mesh map and using the least squares approximation to obtain a 
traction field. 
 
Standard CTFM is done by measuring bead displacement on the top layer of the 
PAA hydrogel. Only a negligibly soft and thin layer of PSMA (~4 kPa, 10 – 20 nm) 
separates the cells from the beads in the hydrogel which makes this system ideal 
for using the MATLAB algorithm to determine cell tractions. This is widely used for 
CTFM184-186 which makes it a control experiment to compare FEM and CTFM. No 
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significant differences were observed between methods (Figure 39) which serves 
as a validation of the finite element model. 
In contrast, differences in maximum tractions stress and total force were shown in 
cells on PEA and PMA when comparing FEM and CTFM, most remarkable in PMA. 
The standard method (CTFM) is highly dependent on the mechanical properties of 
the system as a whole (polymer and hydrogel). However, modelling takes into 
account several factors for every layer of the system individually. These include: 
stiffness, Poisson ration, and thickness of each component of the system.  
When the stiffness of the polymer-hydrogel bi-layer were measured by force 
spectroscopy values were 22 and 25 kPa for PEA and PMA respectively. This is 
clearly a combination of the very thin and stiff polymer (70 – 100 nm; 400 – 800 kPa) 
with a relatively thicker, softer hydrogel (500 µm; 3.5 kPa). The proportions of which 
remain unclear. The FEM method was used to determine the forces on the surface 
of the FN-coated polymers by processing the transmission of forces from the surface 
of one substrate (polymers) to the surface of another (hydrogel). 
It has been well documented that cells exert larger forces on stiffer surfaces202-204. 
With FEM, cells appear to exert more force on the PMA compared to PEA and 
PSMA with a maximum traction stress of ~790 Pa and total force of ~1350 nN 
(compared to ~300 Pa and ~535 nN on PEA). With a higher Young’s modulus and 
thicker polymer layer on PMA, bead displacement in terms of distance was 
comparable to other surfaces.  
Although there are clear differences in traction force measurements on PEA and 
PMA, it remains unclear if this is solely due to the difference in polymer stiffness 
(and thickness) or if the conformation of FN on the surface plays a role in cell forces.  
 
3.4.4 FAK and downstream signalling 
FAKis a protein-tyrosine kinase that is main component of FAs, and is responsible 
for signalling pathways involved in cell migration62, 205. The activated phosphorylated 
form of the protein (pFAK) is available in very little quantity and undetectable using 
certain techniques such as in-cell western74 (Figure 40), but is a potent signalling 
protein63, 206, 207. Studies have shown that FAK, in conjunction with Src, contributes 
to integrin clustering which leads to: FA formation, MMP degradation leading to 
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cancer metastasis, and, actin polymerisation208. It is therefore a key factor in cancer 
progression and a potential therapeutic target.  
In order to determine the effect of FA conformation on FAK/pFAK expression, 
standard Western blot and in-cell western techniques were used. However, pFAK is 
not expressed in large amounts within cells making protein quantification by these 
methods difficult (Figure 40 and Figure 43). Furthermore, previous studies 
measuring the expression of FAK/pFAK showed higher expression of pFAK in cells 
on fibrillar FN on PEA compared to globular FN on PMA72,209.  
Immunostaining of FAK and pFAK on both polymers revealed striking differences in 
pFAK organisation and distribution (Figure 44) while having similar amounts of the 
phosphorylated form (Figure 47). Phosphorylated FAK staining was more 
pronounced at the edges of cells on PEA compared to PMA, similarly to vinculin 
immunostaining. Interestingly, pFAK was localised mostly in the cytoplasm of cells 
on PMA and not organised in traditional FAs suggesting that globular FN is not 
conducive to integrin clustering and FA formation. This is translated to a lower FA 
count (Figure 32), and suppressed cell motility (Figure 36A) on PMA compared to 
PMA.  
Furthermore, using PND-1186 to block FAK lead to a decrease in identifiable FA 
associated pFAK count as well as a decrease in fluorescent intensity on both 
polymers (Figure 45B and Figure 47A). This decrease in pFAK activity lead to 
supressed cell motility mostly in PEA (Figure 36) whereas mobility of cells on PMA 
was already limited due to the lack of organisation of phosphorylated FAK.  
 
3.5 Conclusions 
DU145 human prostate cancer cells have been shown to interact with FN via both 
α5β1 and αvβ3 which are responsible for cell adhesion and migration. Both the RGD 
and PHSRN are needed to bind integrin α5β1 whereas integrin αvβ3 binds solely to 
RGD. Although the RGD sequence is thought to be the main actor in cell attachment 
and motility whereas PHSRN is seen to be an auxiliary sequence, these studies 
demonstrate that both are equally important playing specific roles. The RGD cell 
binding domain being needed for cell anchorage, whereas the PHSRN sequence 
promotes migration.  
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In this study, it has been demonstrated that the use of materials capable of inducing 
differences in FN conformation and domain availability is capable of shedding light 
on the complex interactions between cells and a key protein of the ECM. The similar 
physico-chemical properties of PEA and PMA allow binding of FN, albeit in different 
conformations, and present similar cell behaviour such as cell attachment, FA size, 
drug resistance and traction forces. The value of using these materials are their 
ability to control the availability of specific sequences of FN leading to drastic 
changes in cell motility via changes in intracellular signalling.  
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4 Chapter 4: From 2D to 3D – DU145 
invasion and degradation of functionalised 
PEG hydrogels 
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4.1 Introduction 
4.1.1 The importance of 3D models in cancer research 
Metastasis is the process by which tumour cells migrate away from the main tumour, 
using circulatory and lymphatic systems, and gets imbedded in a distant tissue. This 
requires for the cell to sustain various microenvironmental signals and influences. 
Determining factors in this process are the biochemical composition and mechanical 
properties of the surround tissue. Cells use these external cues to undergo the 
epithelial-mesenchymal transition which is a change in the cell phenotype causing 
the activation of transcription factors and an increase in the cell’s ability to migrate 
and invade other tissue110, 111. Although this is a widely-understood process, many 
of the specific mechanisms involved remain unknown. The molecular and genetic 
mechanisms involved have been studied in 2D on a monolayer of cells but the 
biomechanical influences remain unclear. The use of 3D models in cancer research 
is therefore paramount for elucidating the roles of the ECM composition and 
structure, as well as the stiffness of the surrounding tissue210, 211. Many 3D models 
are currently being used to bridge the gap between 2D monolayer cell systems and 
in vivo studies212. Multicellular tumour spheroids are used to test chemotherapeutic 
agents and drug delivery systems213, 214 whereas cell excreted ECM such as 
collagen, matrigel and hyaluronic acid (HA) as well as scaffolds such as silk protein, 
poly(ethylene glycol) (PEG), and poly(lactide-co-glycolide) (PLG) are used to study 
cell-cell and cell-ECM interactions in proliferation and migration211, 215.  
 
4.1.2 Advantages of functionalised PEG-based hydrogels 
PEG-based hydrogels are highly tuneable systems that are used in regenerative 
medicine and drug delivery216, 217. This system also has the potential to help 
understand the interaction of cells with specific ECM protein sequences such as the 
RGD and PHSRN motifs on fibronectin as well as growth factors. It has the 
capabilities of mimicking the ECM, more specifically FN, with the possibility to tune 
biophysical and biochemical properties such as adhesion site density, MMP-
degradable sites, as well as stiffness, all of which are intricately involved in cancer 
cells and their ability to migrate218, 219.  
A main advantage of using these synthetic hydrogels compared to natural matrices 
is that any changes to the stiffness by controlling protein concentration also leads 
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to variability in adhesive site quantity and density. PEG-based hydrogels, however, 
offer the possibility to modulate mechanical and biochemical properties 
independently of one another (Figure 50). 
 
 
Figure 50: Schematic representation of PEG hydrogels with cross-linking and 
cell binding options. (A) PEG hydrogels consist of a PEG-4 maleimide 
backbone, a crosslinker that is either degradable (green) by MMPs secreted 
by the cell220 or non-degradable (red)221, and a cell binding sequence (blue) 
such as RGD of PHSRN. (B) Hydrogels obtained are either degradable by 
MMPs or non-degradable. Fine-tuning includes using a mix of degradable 
and non-degradable crosslinkers to control gel degradation time or 
modulating the amount of cell binding sequences to control cell binding. 
 
These characteristics make this system ideal for understanding the specific 
interactions of cancer cells with the cell binding domain and synergy sequence of 
fibronectin as well as understanding cell migration via the degradation of ECM 
protein cleavable sites.  
 
 108 
 
4.1.3 Hypothesis and experimental aims 
We hypothesise that functionalised PEG-based hydrogels are an effective platform 
to study simple cell-ECM interactions within a 3D environment. The aims of this 
study are therefore to evaluate the potential of 4-arm PEG-based hydrogels with 
RDG (and eventually FN fragments) as a tool to understand cancer cell adhesion 
and invasion through the degradation of MMP-cleavable sites and to assess the 
limitations of this system.  
 
4.2 Materials and methods 
4.2.1 Hydrogel preparation 
Hydrogels were made according to the protocol described by Andres Garcia216. 4-
arm PEG-Maleimide (PEG-4MAL) macromer was first dissolved and mixed with 
RGD peptide with a 1:1 PEG-4MAL:RGD ratio allowing the binding of one RGD 
peptide to one arm of the 4-arm PEG therefore leaving 3 arms free for cross-linking. 
The cross-linker was then mixed in until gels were formed (Figure 51).  
 
Figure 51: Principle of RGD-functionalised PEG-4-MAL with a MMP-
degradable cross-linker. Gels are formed using 4-arm PEG-Maleimide (PEG-
4MAL), and RGD sequence (GRGDSPC) and a cross-linker with a MMP-
degradable sequence (-VPMSM-: degraded by MMP1 and MMP2220). 
Peptide sequences bind to 4-arm PEG via the thiol group of the cysteine 
amino acids which react with the maleimide group of PEG in a process known 
as Michael’s addition reaction. It is possible to control gel stiffness by 
modulating the proportion of PEG-4MAL to the cross-linker. 
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The following Table 10 depicts the reagents used for the hydrogels. 
Table 10: Reagents used for hydrogels 
PEG used PEG-4MAL (4 arm PEG with 
maleimide) 
Cell binding sequence GRGDSPC 
Dithiol protease-cleavable cross-linker GCRDVPMS↓MRGGDRCG 
 
PEG-4MAL was first reacted with a constant concentration of 2 mM GRGDSPC cell 
binding sequence at different MAL:RGD ratios depending on desired gel stiffness. 
RGD-functionalised PEG was then cross-linked with the dithiol protease-cleavable 
cross-linking peptide (cleaved by MMP1 and MMP2220) at a 1:1 molar ratio of 
cysteine (2 per peptide) to remaining reactive group (MAL). All reactions were done 
in PBS in order to have a constant pH of 7.4. 50 µl gels were made at 4%, 7.5% and 
10% wt/vol according to the following Table 11. 
 
Table 11: Composition of gels 
Gels (wt/vol) 4% 7.5% 10% 
PEG-4MAL (20 µl) 36 mg/ml 67.5 mg/ml 90 mg/ml 
2 mM RGD (10 µl) 1.4 mg/ml 1.4 mg/ml 1.4 mg/ml 
VPM (20 µl)  2.6 mg/ml 6.1 mg/ml 8.6 mg/ml 
 
PEG-4MAL and peptides were weighed, dissolved in PBS, mixed and left for 1h at 
room temperature in order to form gels. 
 
 
 
 
4.2.2 Force spectroscopy 
 110 
 
Force spectroscopy was attempted on functionalised PEG hydrogels. This was done 
by AFM using the Nanowizard 3 AFM from JPK in immersed conditions (water) with 
a 10 µm radius bead (spring constant 0.3 N/m). Due to the rough surfaces of 
hydrogels, force spectroscopy was only performed on 7.5 and 10% hydrogels. 
 
4.2.3 Live/dead assay 
Gels were prepared as previously described (Table 11) and seeded inside with 
1.5x103 cells/mm3 of gel. Gels were then kept at 37°C with 5% CO2 for up to 7 days, 
changing media every 2-3 days. Live/dead assay was then carried out on gels after 
3 days and 7 days. Cells were seeded onto tissue culture plastic for a positive and 
negative control. Positive controls were incubated and stained normally whereas 
negative controls were treated with methanol for 5 minutes before being rinsed and 
stained.  
After 3 or 7 days incubation, gels were rinsed with PBS and incubated with live/dead 
reagents. Images were then taken using an epifluorescent inverted microscope 
showing live cells in green and dead cells as red. 
 
4.2.4 Cell invasion 
In the case of cell invasion, gels were prepared as described (Table 11) in a 96-well 
tissue culture treated plate in an attempt to have a flat enough surface to seed cells 
upon. Gels were prepared at 4%, 7.5% and 10% w/v, left in PBS overnight, and 
seeded with DU145 human prostate cancer cells on top on the gels 
(1.5x103 cells/cm2). Some cells were incubated using media containing 5 µM of 
MMP inhibitor (364205, Calbiochem). 
Cell were then fixed with 4% formaldehyde and stained with DAPI. Images were 
then taken using an AxioObserver.Z1 with a scanning stage and a 10x objective. 
Images were taken for a maximum depth (z) between 300 – 900 µm with 10 µm z 
intervals. A 3D model was then reconstructed in post processing using the ZEN lite 
program from Zeiss microscopy.  
  
4.2.5 Gel degradation 
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Gel degradation experiments were carried out on 7.5% gel only. Gels were prepared 
with 1.5x103 cells/mm3 (for 30 µl – 30 mm3 gels) of hydrogel and weighed after 
seeding and every 3-4 hours for 30 to 72 hours using Eppendorf tubes with filter 
baskets. Tubes were first weighed empty and with gels right after they were formed 
with cells to establish the ‘dry’ weight of the gel without completely allowing it to 
dehydrate. Gels were then incubated with media for 3 – 4 hours before removing 
media by first centrifuging tubes to allow media to be drained through the pores of 
the filter and then removed (Figure 52). Tubes were then weighed with gels and this 
process was carried out for 1 to 3 days. This method is a complex and inaccurate 
way to indirectly determine gel degradation. Other methods such as using a 
rheometer to measure the mechanical properties of the gel until it is no longer 
detectable222 or by the fluorescamine assay which detects primary amines at the 
picomole range223 are more robust ways of measuring gel degradation.   
 
Figure 52: Gel degradation measurement process. Tubes were first weighed 
empty and gels were formed in the tubes in sterile conditions with or without 
cells seeded into them. Tubes were then incubated at 37°C with DU145 
growth media and the weight of the gels were measured every 3-4 hours by 
carefully removing the media through centrifugation and pipetting and 
weighing in sterile conditions. Fresh media was then introduced to each tube 
until ready to measure again. 
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Experiments studying degradation of gels by cells were carried out using the VPM 
cleavable peptide but also PEG-Thiol (PEG-SH), an uncleavable cross-linker. The 
same ratio of PEG-4MAL:VPM was used for PEG-4MAL:PEG-SH, which was 1:3.  
A control experiment was also carried out without cells but with the use of 
collagenase, a known ECM cleaving enzyme224. Collagenase was used at 10 µg/ml 
and 100 µg/ml RGD-PEG gels cross-linked with VPM and PEG-SH. 
 
4.3 Results 
4.3.1 Gel stiffness 
Polymers with different wt/vol percentages have different mechanical properties. 
Modifying the PEG/Cross-linker ratio leads to differences in stiffness and even in 
the aspect of the gels. Higher wt/vol percentage gels are stiffer, more cloudy and 
easier to handle whereas lower percentage gels are translucent and much more 
difficult to handle (Figure 53).  
 
Figure 53: 10% wt/vol (left) and 7.5% wt/vol (right) functionalised PEG 
hydrogels.  
 
The lowest percentage of hydrogel (4% wt/vol) was very liquid, making mechanical 
characterisation impossible as opposed to stiffer gels.  
Higher percentage gels (10%) were measured to have a Young’s modulus of 
~2.8 kPa whereas 7.5% gels were approximately half that at ~1.4 kPa. Although this 
is not exactly in line with reports by Garcia et al., it has been demonstrated that gel 
stiffness can easily be modulated to mimic tissue stiffness for in vitro experiment 
closer resembling in vivo conditions (Figure 54).  
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Figure 54: Young’s modulus of 7.5% and 10% wt/vol PEG hydrogel 
functionalised with RGD, with MMP degradable cross-linkers. 
 
4.3.2 Short term cell viability 
Cell viability within hydrogels was measured by live/dead assay over a 1-week 
incubation. Only 7.5% gels were used in this instance.  
After 3 days, 90% of cells were found to be alive within gels. After 7 days, no dead 
cells were detected with 5-10% of cells remaining compared to initial seeding 
(Figure 55). This is thought to be due to the degradation of the gel via cleavage of 
VPM sequences by MMPs secreted by the cells, allowing them to escape the 
hydrogel and be rinsed away during media changes.  
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Figure 55: Live/dead assay of DU145 after 3 or 7 days incubation. (A) 
Positive control of cells on TCP. (B) Negative control of cells on TCP after 
being treated with methanol for 5 minutes. (C) Cell within gels after 3 days. 
(D) Cell within gels after 7 days. Scale bar: 500 µm. 
 
4.3.3 Invasion and degradation 
4.3.3.1 Cell invasion 
Cells were seeded onto functionalised PEG hydrogels in a 96-well plate with and 
without a MMP inhibitor (Figure 56).  
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Figure 56: Invasion of DU145 cells stained with DAPI 24h after seeding onto 
PEG hydrogels of different wt/vol concentrations with and without MMP 
inhibitor. PEG gels were used at 4% (A), 7.5% (B) and 10% (C) wt/vol. The 
dotted red line represents the approximate gel surface whereas the dotted 
yellow oval indicates cells that have invaded the surface. With the MMP 
inhibitor cells remain at the designated gel surface, however, without the MMP 
inhibitor, cells penetrate the gel going lower than the designated gel surface 
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by degrading the gel. Although it is thought that the degradation occurs through 
the secretion of MMPs, the type of MMP is not clear. 
 
In each case, cells appear to invade the gel in media with no MMPi whereas with 
MMPi cells appear to remain in the same plane. These results suggest that cell 
invasion within PEG hydrogels cross-linked with VPM is due to MMPs produced by 
the DU145 cells. 
 
4.3.3.2 Gel degradation 
Gel degradation by MMPs secreted by cells and also by collagenase was measured.  
Hydrogels cross-linked with VPN swelled 3 – 5 times their original size and were 
able to maintain a consistent size for the first 30 hours after which cells began 
degrading to the point where gels were completely dissolved within 48 hours (Figure 
57A and C). A similar trend was observed when cells were seeded into gels, 
however, degradation was evident with collagenase with gels losing mass after 24 
hours with 10 µg/ml of collagenase and completely degraded hydrogels after 12 
hours with 100 µg/ml.  
Collagenase was shown to be ineffective on the PEG-SH cross-linked hydrogels 
with gels swelling 1.5 to 3 times original weight and maintained it over 30 hours even 
with the highest concentration of collagenase (Figure 57B). Strangely, the hydrogel 
degraded with or without cells after 48 hours (Figure 57D).  
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Figure 57: Degradation of functionalised PEG hydrogels with VPM or PEG-
SH cross-linkers via (A) collagenase or (B) cell secreted MMPs. Lower 
concentrations of collagenase (10 µg/ml) started degrading the VPM cross-
linked gels after 24 hours whereas the highest concentration (100 µg/ml) 
degraded gels almost immediately. Collagenase had no effect on PEG-SH 
cross-linked gels. VPN and PEG-SH cross-linked gels were both degraded 
by cells. 
 
4.4 Discussion 
4.4.1 Functionalised PEG gels as a 3D model 
These gels provide a highly tuneable system as a viable 3D model in biomaterials 
research. Unlike natural networks and matrices such as Matrigel and collagen gels, 
it is possible to precisely determine the quantity of biological components capable 
of eliciting cellular response such a cell binding sequences and growth factors216, 
225, 226. In this study the ratio and type of cross-linker was chosen while using a 
constant amount of RGD. However, studies have been carried out by binding FGF-
2 and VEGF to PEG in order to modulate angiogenesis225. This can allow the study 
of potential peptide/growth factor combinations for increased cellular response74. 
Furthermore, the use of higher molecular weight PEG such as 8-arm PEG have 
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been shown to confer even more control on the hydrogel’s composition with a 
broader range of possibilities in terms of combinations227.  
Just as with polyacrylamide hydrogels, mechanical properties of PEG hydrogels can 
be fine-tuned in order to mimic in vivo tissue conditions (Figure 54). This aspect is 
very useful in the study of cancer migration, the phenomenon of durotaxis, and, 
elucidating the cause and effect relationship between cancer progression and 
tumour stiffness. 
 
4.4.2 Challenges and limitations 
This is a preliminary study which has provided a general understanding of the use 
and potential of PEG hydrogels but has also highlighted many of its limitations. PEG 
hydrogels are a useful model for understanding specific cell-peptide or cell-growth 
factor interactions, which makes this 3D system very promising but the use of 
peptides as cross-linkers can become relatively costly. Furthermore, the ability to 
fine-tune this system is directly correlated to the number of arms the PEG backbone 
has. With 4-arm PEG in order to have consistent gels at least two arms are needed 
for cross-linking, therefore limiting functionalisation and degrees of degradation 
possibilities.  
Results obtained in this study were mostly qualitative, showing the potential of this 
system as a 3D cancer model all while showing its limitations. Although it is possible 
to control gel stiffness, incorporating cells homogeneously within gels can prove to 
be challenging due to different polymerisations times.  
 
4.5 Conclusions 
In this study, PEG-based hydrogels have been shown to be a very adequate system 
to study the effects of specific peptides on cancerous cells in a 3D environment. It 
is possible to fine tune the degree of cell binding and gel degradation by simply 
changing the peptide content without sacrificing cross-linking density therefore 
compromising mechanical properties.  
This is a simple and controlled method that offers the possibility to use numerous 
combinations of peptide sequences and is capable of completing a bigger picture 
alongside 2D systems in understand cell-protein interactions. 
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5 Discussions and outlook 
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5.1 Understanding and characterising the material-protein and protein-cell 
interfaces  
The cell-protein interface is an important factor in determining cell behaviour. Cells 
are able to interact with their extracellular matrix via integrins. These allow bi-
directional signalling between cells and their environment. Outside-in signalling 
occurs when specific sequences of ECM proteins or growth factors are presented 
to the cell, initiating downstream signalling which ultimately leads to changes in cell 
behaviour (proliferation, migration, apoptosis, etc.). Inside-out signalling is 
characterised by the effect cells have on their environment, leading to changes in 
ECM organisation via production of cell secreted ECM (collagen, FN) or degradation 
of the existing ECM by hydrolysis due to the secretion of MMP enzymes. Both forms 
of signalling are responsible for many of the processes involved in the formation and 
maintenance of the TME. These include cell growth and proliferation, angiogenesis, 
hypoxia, epithelial-mesenchymal transition, metastasis, and, drug resistance. In 
order to understand these behaviours, using the appropriate systems and materials 
is important. 
Understanding that specific sequences of ECM proteins induces changes in cell 
behaviour highlights the importance of the choice of materials used to present the 
proteins to the cells. Conventionally, cell culture-treated tissue culture plastic is used 
which is usually coated with ECM proteins. However, the types of proteins used or 
their respective proportions remain unclear making it unfeasible to study specific 
cell-protein interactions. In order to do so, there is a need to be able to control ECM 
protein conformation and specific domain availability on the protein. 
 
5.2 Controlling cell behaviour by using FN-coated poly(alkyl) acrylates 
FN plays a vital role in cell signalling with various domains with which cells and other 
ECM protein can interact with. Many studies have shown its involvement cell 
binding, proliferation and migration mainly via the RGD and PHSRN synergy 
sequences located on the FN-III7-10 repeat domain (Figure 4). It is secreted as a 
soluble dimer which undergoes conformational changes, promoting its 
polymerization into insoluble fibres. This process occurs naturally and is cell-
mediated. However, when adsorbed unto material surfaces they induce the 
unfolding of FN, it undergoes material-induced fibrillogenesis. We demonstrate that 
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upon adsorption to poly(ethyl acrylate) (PEA), FN undergoes fibrillogenesis leading 
to the formation of a fibrillous network. When adsorbed unto poly(methyl acrylate) 
(PMA), a substrate with very similar physico-chemical properties (Table 1), FN 
remains folded in a globular conformation (Figure 17). This leads to differences in 
the presentation of specific domains of FN when the protein is unfolded on PEA 
compared to when it is globular on PMA. We demonstrate that with similar amounts 
of protein are absorbed onto each surface, although the RGD cell binding domain 
is equally available the PHSRN synergy sequence is less available on PMA 
compared to PEA (Figure 19). This difference is the basis upon which cell studies 
were carried out by understanding that it has significant consequences on integrin 
biding and therefore cell behaviour. Cell attachment, FA formation and quantification 
were assessed using L929 mouse fibroblasts firstly and then using DU145 human 
prostate cancer cells. This human cancer cell line was subsequently used to study 
cell migration, cell traction, intracellular signalling and drug treatment when seeded 
onto FN-coated PEA and PMA. 
 
5.3 Studying focal adhesion formation and cell migration 
Cell attachment and FA formation are a direct response to contact with FN, the 
conformation of which is modulated by the underlying material it is presented to. 
Here we show that L929 mouse fibroblasts and DU145 human prostate cancer cells 
initially attach to the surface within the first 20 minutes of contact (Figure 23A and 
Figure31) via FN and that within a relatively short time of 2-3 hours are able to form 
FAs (Figure 21 and Figure 34). Furthermore, DU145 cells began migrating within 
the first 3 hours after seeding (Figure 36) indicating the mobile dynamic of FAs after 
initial attachment with continuous association of focal complexes which develop into 
FAs at the leading edge of the cell, coupled with disassociation of FAs at the 
opposite end leading to movement. This is commonly referred to as FA turnover and 
is responsible for cell motility228.  
FA characteristics such as size, amount and area were determined 2-3 hours after 
seeding and represent a fixed point in time. Here we looked at FA formation as well 
as cell migration of cells on PEA, PMA and glass coverslips coated with FN. FAs 
were more developed around the edges of the cells on the fibrillar FN of PEA and 
were also larger with more FAs compared to cells on globular FN on PMA. This is 
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thought to be a sign of cells being firmly attached to the surface on which FN is 
stretched out in a network conformation. Interestingly, upon studying the migration 
of DU145 cells on these substrates, cells were more mobile on PEA compared to 
PMA indicating that the more developed FAs on PEA are a result of higher activity 
in FA turnover leading to higher motility even when cells are treated with a FAK 
inhibiting cytostatic drug (Figure 36). This theory could be further developed by 
studying FA turnover using fluorescently-labelled FA proteins such as paxillin or 
vinculin in live imaging228. We can therefore conclude that the exposure of the RGD 
and PHSRN sequences of FN, due to the conformation taken upon adsorption to 
PEA and PMA, have a significant effect on FA formation and cell mobility. This 
brings into question the underlying mechanisms of the cell’s interactions with these 
specific FN sequences.  
 
5.4 Clarifying the underlying mechanisms involved in the cell’s interaction with its 
environment 
It is well known that the integrin α5β1 interacts with both the RGD and PHSRN 
sequences whereas the αvβ3 integrin interacts preferentially with the RGD domain. 
The integrins, once bound to FN via these sequences, recruit other proteins such 
as talin and vinculin to form a focal complex which then develops into FAs by 
recruiting other FA proteins such as paxillin and FAK (Figure 6). FA being directly 
coupled to actin filaments are responsible for cell motility through their association 
and disassociation along the leading edge of the cell. FAK plays a critical role in the 
formation of FAs as its phosphorylated form (pFAK) is thought to be involved in the 
signalling pathways of migration such as MMP secretion and actin polymerisation 
making it a prominent therapeutic target. Both FAK and pFAK were shown to be 
expressed equally within DU145 cells on FN-coated PEA and PMA. The addition of 
a novel FAK inhibitor, PND-1186, was shown to decrease their expression in both 
cases. Although no differences were observed in pFAK expression with and without 
the addition of PND-1186, cells were more mobile on PEA.  
Furthermore, blocking the RGD and PHSRN sequences of FN highlighted the role 
of integrins in cell adhesion and migration. Here we propose that cell anchorage and 
adhesion are dependent on the RGD cell binding domain via αvβ3 whereas cell 
motility is dependent on the combination of the RGD and PHSRN sequences via the 
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α5β1 integrin. When cells attach to FN via RGD these integrins combined form a 
solid bond between the cell and the ECM protein. This was confirmed when the 
RGD domain was blocked with HFN7.1 leading to cell not attaching to surfaces 
(Figure 31). However, blocking the PHSRN synergy sequence partially affected cell 
attachment of cells on PEA. When motility was studied by wound healing assay, 
cells were shown to be more mobile on PEA (Figure 36) confirming that the PHSRN 
sequence, exposed more on fibrillar FN on PEA compared to globular FN on PMA, 
promotes cell migration along with the RGD cell binding domain via the α5β1 integrin. 
When cells begin migrating we propose that the αvβ3 integrin detaches from the RGD 
sequence allowing cells to interact with FN using only one integrin heterodimer, 
allowing a more dynamic relationship between the cell and the ECM, leading to 
quicker FA turnover.  
In order to further study the effect of the RGD and PHSRN sequences on cell 
adhesion and migration specific studies could be carried out such as the use of 
modified FN with inactivated sequences (RGE instead of RGD, PHSCN instead of 
PHSRN), assessing cell migration in a 3D setting, and studying cell tractions on 
polymers. These modified forms of FN would provide a more accurate study of cell-
FN interactions. The use of the antibodies HFN7.1 and mAb1937 to block the RGD 
and PHSRN sequences respectively may pose an issue as they are relatively 
cumbersome (150 kDa) compared to FN (220 kDa). Furthermore, due to their size 
and the proximity of the domains they are blocking, it is not clear if blocking one 
domain with an antibody limits access to the other domain by the cell’s integrins or 
even the other antibody. Removing these antibodies would therefore simplify the 
interactions between the cell and FN.  
 
5.5 Developing novel methods for analysis of cell traction on polymers 
CTFM is a common method used for the evaluation of the exertion of cellular forces 
on a given material surface such as functionalised polyacrylamide (PAA) or 
nanopillars229. These methods determine traction forces by simply knowing the 
mechanical properties of the material surface and the displacement induced by the 
cell at the cell-material interface (Figure 37). Here we use a bi-layered system 
consisting of a layer of PAA embedded with fluorescent polystyrene nanoparticles 
coated with a thin layer of PEA or PMA in order to compare the forces exerted by 
 124 
 
cells on surfaces on which FN is in an extended fibrillar state on PEA or in a globular 
state on PMA. Nanobeads were not embedded directly into polymers due to the fact 
that they would dissolve in the polymer solution (prepared in toluene). This offers a 
unique opportunity to develop a method for measuring cell traction on a two-layered 
system that possesses vastly different mechanical properties between layers (Table 
8) by using computational modelling. We can conclude from the results obtained 
that the majority of the force exerted by cells is due to the mechanical properties of 
the polymer-hydrogel system as there a clear correlation between the thickness and 
stiffness of the polymer layer and the maximum traction stress and total force 
exerted by the cell. However, an argument can be made that the conformation of 
FN on the surface plays a role in cell traction. Knowing that cells adhere to surfaces 
such as FN-coated PMA that present primarily the RGD sequence, via 2 sets of 
integrin heterodimers (α5β1 and αvβ3), they are more firmly attached and exert more 
force on the surface. On surfaces such as FN-coated PEA that present RGD and 
PHSRN cells are more mobile thus exerting less force on its substrate.  
The influence of the mechanical properties versus the protein conformation and 
binding domain presentation could be further elucidated by comparing the traction 
of cells on polymers with the same thickness and also by blocking the RGD and/or 
PHSRN sequences. The model does take into account the thickness and stiffness 
of the polymer layers however, they have no apparent linear correlation with the 
traction stresses exerted by cells on PEA and PMA.  
Once fully developed and optimised, this model shows potential of being a more 
appropriate method for understanding cell traction on more complex surfaces such 
as the presented bi-layered system on which standard CTFM techniques are not 
possible. It also has other potential applications such as modelling cell traction and 
migration on stiff tissue like bone in tissue regeneration.  
 
 
5.6 Studying cell behaviour in a simplified 3D model 
3D models are often used to understand more complex phenomena within tissue 
such as vascularisation. They are representative on in vivo conditions but fail to 
shed light on specific cell-cell or cell-ECM interactions as with 2D systems. We 
propose the development of a model that takes into consideration the 3D aspect 
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which mimics in vivo conditions as well as looking at specific interaction between 
the cell and its microenvironment. These PEG-based hydrogels are highly tuneable 
and offer a wide range of possible combinations of mechanical properties, 
degradability, and peptide presentation to further understand the role of specific 
sequences of ECM proteins on cell behaviour in a controlled 3D setting.  
Here we use PEG hydrogels functionalised with RGD and a MMP degradable cross-
linker with controlled stiffness’s and are able to maintain viable cells within them for 
up to 1 week, until cells completely degrade the gels (Figure 55C and D). Moreover, 
cells are shown to invade the gels through MMP secretion (Figure 56) highlighting 
its potential in further understanding the processes of metastasis and ECM 
degradation. The results presented in this study opens the door for understanding 
the role that the PHSRN synergy sequence of FN would play in cell encapsulation 
and behaviour. A proposed experiment would be to study cell migration within a 
non-degradable gel containing both the RGD and PHSRN sequences versus a non-
degradable gel containing RGD only. This would shed light on the specific roles of 
both domains on cell mobility in a 3D system.  
 
5.7 Future work 
Although extensive research has been carried out into understanding material-
protein and protein-cell interactions, there are many more mechanisms involved that 
have yet to be elucidated using both the FN-coated material platform as well as the 
functionalised PEG hydrogel system. 
 
5.7.1 FN-coated polymer platform 
This system can be further developed to take into account other ECM proteins that 
are involved in cancer progression or growth factors such as VEGF that bind to FN 
and may possibly alter cell behaviour.  
Another avenue would be to study the reorganisation of the FN on the surface of the 
polymers by the cells. Knowing that the cells secrete MMPs as well their own FN it 
would be possible to stain and observe the secreted FN with a specific cellular-FN 
antibody. This would give insight into how cells interact with their surroundings 
depending on the conformation of FN.   
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Furthermore, studying the downstream signalling of FAK (pFAK, Src, PI3K,etc.) by 
Western blot or PCR would help to understand the effects of FN conformation on 
cell motility. 
 
5.7.2 Functionalised PEG hydrogel system 
This preliminary study of functionalised PEG with MMP-degradable crosslinkers 
shows promise in having a 3D system that is easily tuneable and offers many 
possibilities for further research.  
Comparative studies with other established 3D systems such as Matrigel® and 
polymer scaffolds would further reveal the advantages and drawbacks of the 
system. Moreover, the use of 8-arm PEG would allow for more crosslinking and 
functionalising possibilities. This would be useful to study degradation speed (using 
a mixture of degradable and non-degradable crosslinker sequences), cell adhesion 
(modulating the amount of RGD) and cell proliferation. A more ambitious study 
would be attempting to use large sequences of FN or other ECM proteins as cross 
linkers. Incorporating growth factors within the system while controlling the 
degradation rate would allow cells to proliferate and possibly form their own ECM in 
3D.  
 
 
 
 
 
 
 
 
 
6 Conclusions 
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Advances in biomedical engineering have allowed for more in depth understanding 
of cell function. These have shown to be useful for the advancement of cancer 
research by providing further understanding of the specific processes involved 
through breaking down the TME.  
Here, we used poly(alkyl acrylates) to be able to direct the conformation of FN, a 
key protein of the extracellular matrix. We have managed to show that these 
material substrates, with very similar physico-chemical properties, are able to 
modulate FN conformation and therefore cell behaviour. The change in FN 
organisation has shown to influence FA formation and organisation, cell migration, 
FAK/pFAK layout, and traction forces.  
Furthermore, this has played an important part in clarifying the role of the RGD cell 
binding domain as well as the PHSRN synergy sequence in cell adhesion and 
migration. With the cell anchoring to the surface using the RGD sequence via 
integrin αvβ3 and cell motility being directed by both the RGD domain and PHSRN 
synergy sequence via integrin α5β1. This can potentially lead to the development of 
new therapies specifically targeting cancerous cells at the FN-integrin interface to 
prevent cells from spreading.  
Finally, we propose a 3D model that can replicate and study specific cell-FN 
interactions with RGD and PHSRN and provides a system that more closely mimics 
in vivo conditions.  
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